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THE IPU has called on the PSI to 
liaise with the Department of 
Health and the HSE to implement 
a nationwide DUMP campaign, 
funded by the HSE, which urges 
consumers to ‘Dispose of Unused 
Medication Properly’ (DUMP).
The pharmacy union made the 
call in its submission to the PSI on 
its ‘Draft Guidelines on Sourcing, 
Storage and Disposal of Medicinal 
Products within a Retail Pharmacy 
Business.’
According to the IPU “the draft 
guidelines suggest that patients 
should be encouraged to return 
unwanted or expired medicinal 
products to the pharmacy for 
disposal. Whilst many pharmacies 
provide this service as a gesture 
of goodwill to their patients, it is 
unfair to expect pharmacies to 
cover the considerable cost of 
such disposal. Some HSE areas 
provide a DUMP scheme through 
pharmacies in their area but many 
more do not.”
“The PSI should be cognisant 
of the costs involved in expect-
ing pharmacies to provide such 
a service and should liaise with 
the Department of Health & 
Children and the HSE to ensure 
that a DUMP scheme, funded by 
the HSE, is put in place nationally 
before imposing such a require-
ment on community pharmacies,” 
the IPU’s submission stated.
In its submission the IPU also 
warns of “a serious risk of” Stand-
ard operating Procedure “(SoP) 
overload and critical patient care 
issues losing out to the mainte-
nance of written procedures and 
practices.”
According to the IPU the latest 
draft guidelines from the PSI 
“impose requirements for a signifi-
cant number of SoPs to be put in 
place”. In fact the union noted that 
the guidelines required a total of 
22 separate SoPs to be developed.
While the IPU stated that it ac-
cepted “that all pharmacies should 
meet the appropriate standards 
in sourcing, storing and disposal 
of medicinal products,” the Union 
“would expect that the PSI be 
cognisant of the practicalities 
from a pharmacist’s perspective 
in relation to the large number of 
SoPs required to implement these 
guidelines.”
“The PSI should seriously review 
the level of bureaucracy now 
being imposed on pharmacists 
and prioritise what they view as 
the critical SoPs,” the submission 
concluded.
The IPU has called for the appoint-
ment of a national Pharmacy 
Coordinator to oversee the im-
plementation of the methadone 
treatment scheme and to support 
pharmacists who deliver the 
service “as a matter of urgency” 
Irish Pharmacist has learned.
According to the union’s 
submission to the current review 
of the Methadone Treatment Pro-
tocol (MTP) being carried out by 
the HSE, the proposed national 
Pharmacy Coordinator would 
“provide support to all phar-
macists already delivering the 
methadone treatment scheme, 
which would in turn encourage 
other pharmacists to participate 
in the scheme.”
The IPU submission, which was 
received by Irish Pharmacist under 
the FoI Act, also stated that such 
an appointment would be “espe-
cially beneficial to pharmacists 
providing the service to patients 
outside the Eastern Region, as 
there has been a serious lack 
of support due to the delayed 
appointment of local Pharmacy 
Liaison officers.”
“As the Scheme is already 
acknowledged to be more cost-
effective when provided through 
pharmacy, this would provide 
long-term savings to the Excheq-
uer,” the IPU added.
The HSE has commissioned 
Professor Michael Farrell, Profes-
sor of Addiction Psychiatry and 
Director of Postgraduate Medical 
Education in the Institute of 
Psychiatry London, together with 
Professor Joe Barry, Professor of 
Population Health Medicine at 
TCD, to carry out a review of the 
Methadone Treatment Protocol in 
accordance with Action 35 of the 
national Drugs Strategy (interim) 
2009-2016.
Under the terms of reference of 
the review Profs Farrell and Barry 
have been asked to review the 
MTP with regard to: maximising 
provision of treatment including 
detoxification, stabilisation, and 
rehabilitation; Clinical Govern-
ance and audit; effectiveness of 
referral pathways; the enrolment 
of GPs, the training of GPs, the 
criteria for Level 1 and Level 2 GPs, 
and the GP co-ordinator role; as 
well as looking at the appropri-
ateness and efficacy of urinalysis 
testing. Additional terms of 
reference include engaging 
with the Department of Justice 
with regard to the prescribing of 
methadone in Garda stations; and 
to review the MTP with regard 
to data collection, collation and 
analysis.
The review is expected to be 
completed some time later this 
month.
iPu calls for Hse funded 
nationwide DuMP campaign
national pharmacy coordinator for methadone 
treatment scheme urgently needed
The vast majority of pharmacists 
– 78 per cent – believe that they 
are asked to provide additional 
services, such as advice, without 
fair and proper compensation a 
major new international survey 
has found.
The findings of the survey 
which were presented at the 
recent International Pharmaceu-
tical Federation (FIP) Congress 
in Lisbon, Portugal also revealed 
that more than 90 per cent of 
pharmacists believe that they 
are key to improving patients’ 
health while 73 per cent provide 
health promotion and manage-
ment services to their patients.
The survey was commissioned 
by Pfizer Inc. in collaboration 
with FIP to better understand 
the needs, concerns and at-
titudes of pharmacists. Inter-
views were held with over 2,000 
community, retail and hospital 
pharmacists in eight countries 
(Australia, France, Germany, Italy, 
Portugal, Turkey, the UK and 
the US) between April and June 
2010.
other results of the survey 
show the degree to which phar-
macists are concerned about 
counterfeit medicines with 61 
per cent stating that the preva-
lence of counterfeit medication 
was a serious issue in their coun-
try. More than half of respond-
ents or 63 per cent believed that 
current policies and technology 
were insufficient to deal with 
counterfeit medicines and 77 
per cent stated that medicine 
packages should have machine 
readable bar codes to ensure 
they are not counterfeit.
Commenting on the results 
Mr Ton Hoek, Chief Executive of-
ficer of FIP said:
“Pharmacists’ roles are 
changing, and we find ourselves 
increasingly working with 
patients and other healthcare 
professionals to prevent and 
treat disease. This survey shows 
that pharmacists welcome this 
expanded role, as it highlights 
what they like doing most – 
helping deliver better patient 
outcomes – while increasing vis-
ibility of pharmacists’ expertise. 
However, we also see an educa-
tion and income gap that will 
need to be closed to ensure the 
pressure on current pharmacists 
isn’t too great, and so that we 
can continue to attract the best 
and brightest to the profession 
in the future’.
Pharmacists believe they provide additional 
services without fair compensation
THE IPU is to host a number of regional meetings 
for members across the country over the coming 
weeks.
on the 04th october a meeting will take 
place in the north West at the Mill Park Hotel in 
Donegal Town and on the 06th of october the 
IPU will host a meeting at the Tullamore Court 
Hotel in Co offaly. The 07th october will see the 
IPU at the Carlton Castletroy Park in Limerick 
and on the 11th there will be a meeting for union 
members in the South at the oriel House Hotel, 
Ballincollig, Co Cork.
The last two regional meetings will be held on 
the 12th october at Dooley’s Hotel in Waterford 
City and on the 14th october IPU members from 
the north East will meet at the Ardboyne Hotel in 
navan, Co Meath.
All meetings will commence at 8pm.
iPu regional Meetings
Pinewood Healthcare pharmacy representative, 
Peadar Flynn (in orange) did a parachute jump for the 
Chernobyl orphanage Fund recently. also pictured are 
Fergal Murphy, Pinewood Healthcare sales Director 
(far left) and abhishek Jain, Pinewood Healthcare 
Commercial business analyst.
Jump for Chernobyl
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Hospital inpatients are, on 
average, likely to miss out 
on almost 10 per cent of 
their medication doses, new 
research presented recently 
at the Royal Pharmaceutical 
Society of Great Britain 
(RPSGB) ’s annual conference 
has shown.
The research, which was 
based on a study carried out at 
Bradford Teaching Hospitals in 
the UK, revealed that overall, 
9.7 per cent of prescribed 
medicines were omitted. 
However, the research found 
that this could be explained by 
a variety of reasons, including 
‘nil by mouth’ policies after 
surgery, specific advice from 
a health professional to 
withhold doses and very often, 
patients themselves refusing 
to take medication.
Drug non-availability 
accounted for missed doses 
in 2.4 per cent of cases. 
The highest proportion of 
doses missed through non-
availability occurred at the 
9am drug round following a 
patient’s admission while drug 
non-availability at admission 
was only a problem in patients 
who had left their supplies of 
medicines at home.
According to the study 
not taking medication at the 
correct time can have serious 
consequences to health for 
those with critical conditions 
or long-term problems such as 
Parkinson’s disease or epilepsy. 
omitting doses of potent 
antibiotics, for instance, can 
lead to delayed recovery from 
infection and a prolonged stay 
in hospital.
Ms nina Barnett, 
spokesperson for the RPSGB 
and a consultant pharmacist 
for older people said: “This 
audit is an example of many 
likely to be taking place in 
hospitals across the country 
following a ‘rapid response 
report’ from the national 
Patient Safety Agency in 
February 2010 on the issue of 
missed medication.
“There is a real need to 
raise staff awareness around 
medicines which must not 
be delayed or omitted. 
Pharmacists can play an 
essential part by developing 
a ‘vital medicines’ checklist, 
which identifies specific 
drugs and situations where 
immediate dispensing is 
required.
Bradford researcher Mr Stan 
Dobrzanski said: “missed doses 
of medicines are especially 
likely to occur immediately 
after hospital admission. 
Patients can help reduce 
the risk of this happening 
by always bringing their 
medicines with them when 
they go to hospital. Initiatives 
are taking place in many 
hospitals to promote this.”
Treating minor ailments 
such as coughs, colds and 
indigestion in community 
pharmacies rather than 
GP surgeries is a very cost 
effective use of health service 
resources according to a new 
UK study.
The research, which was 
presented at the Royal 
Pharmaceutical Society of 
Great Britain’s (RPSGB) annual 
conference which took 
place on the 5th and 6th of 
September last, followed the 
April 2009 launch of the ‘Think 
Pharmacy First’ campaign 
across a number of pharmacies 
in the north of England.
The research was 
commissioned by nHS north 
of Tyne to evaluate the 
campaign and it asked patients 
what they would have done 
if the minor ailments scheme 
was not in place.
When asked, 58 per cent 
said they would have gone 
to their GP had the scheme 
not existed, while 39 percent 
admitted that they would 
have bought the necessary 
medicine from their pharmacy.
Around 0.25 per cent 
responded that they would 
have gone to see their health 
visitor and 0.5 per cent said 
that they would have attended 
the Emergency Department 
(ED) at their local hospital.
Using standard GP and 
ED costs of £36 (€43) and 
£111 (€132) per consultation 
respectively, it was estimated 
the scheme saved over £7,000 
(€8,342) per month across 
nHS north of Tyne.
Mr neal Patel, spokesperson 
for the RPSGP said: 
“Pharmacists and doctors 
need to work together to 
make sure patients get access 
to healthcare in the most 
appropriate way. Many of 
the consultations for minor 
ailments currently taking place 
in GP surgeries could easily be 
managed within community 
pharmacy. We would like 
to see more minor ailments 
services commissioned by 
primary care trusts through 
community pharmacies. 
Pharmacists can then support 
patients to improve their 
self-care, use their clinical skills 
to greater effect and free up 
GPs to focus on more complex 
cases. It’s a win-win situation.”
Ms Ann Gunning, 
community pharmacy 
contracts manager at nHS 
north of Tyne, working on 
behalf of newcastle and 
north Tyneside Primary Care 
Trusts and northumberland 
Care Trust, said: “We are 
delighted with the campaign 
which brings together our 
nHS colleagues including 
pharmacists and GPs to help 
those patients who qualify 
for free prescriptions to have 
greater choice and better 
access to treatment for minor 
ailments.
“Think Pharmacy First is 
using the skills and knowledge 
of pharmacists to provide the 
right treatment for patients 
at the right time, in a place 
which is convenient to them 
in the heart of their local 
community. It does all this as 
well as making best use of nHS 
resources for the public purse.”
nearly 1 in 10 doses of 
prescribed medication 
missed in hospital
study shows cost-effectiveness 
of self-care in pharmacies
IMB disappointed 
by small number of 
applications from 
herbal products
The number of applications 
for the new Tradition 
Herbal Medicinal Products 
(THMP) registration scheme 
as of mid-2010 has been 
"disappointingly small in 
comparison with the number 
of products actually on the 
market," the IMB has said.
According to the IMB 
newsletter (May-August 2010)
under the provisions of the 
Medicinal Products (Control 
of Placing on the Market) 
Regulations 2007, S.I. 540 of 
2007, as amended, "no new 
herbal medicinal product can 
be placed on the market after 
July 2007 without the prior 
approval of the IMB."
"Products which were 
on the market at that time 
can remain on the market 
provided an application is 
made for registration under 
the THMP registration scheme 
and registration is issued by 
the IMB by 30 April 2011. After 
this time, a herbal medicinal 
product may not remain on 
the Irish market legally without 
a marketing authorisation or 
THMP registration."
According to the most 
recent IMB newsletter the IMB 
has published two draft lists 
of herbal substances on its 
website "in order to facilitate 
the registration process 
and give greater clarity to 
companies, some of which 
are continuing to place herbal 
medicinal products on the 
market inappropriately as food 
supplements."
The first list is a list of 
herbal substances, which 
are not considered to be 
suitable for inclusion in food 
supplements. According 
to the IMB “these herbal 
substances are considered to 
be potentially toxic or have 
potent pharmacological action 
which makes them medicinal 
substances under the terms of 
the definition given in Article 
1 of Directive 2001/83/EC as 
amended.”
The second list of herbal 
substances consists of those, 
which are regarded as safe for 
inclusion in food supplements 
when the appropriate part of 
the plant mentioned in the 
third column is used. Products 
containing such herbs would 
take the form of tablets, 
capsules, other solid and liquid 
dosage forms and the dried 
herbs themselves or teas made 
from these herbs. However, 
where concentrated extracts 
or tinctures are used or other 
parts of the plant, safety for 
use in food cannot necessarily 
be guaranteed and potential 
users are advised to consult 
the IMB on individual cases.
According to the IMB, in 
order for herbal substances 
to be included in a food 
supplement, no medicinal 
claim can be made for the 
product on its packaging or 
associated literature.
The IMB also noted that 
the two lists should not be 
considered exhaustive and 
would be added to or deleted 
from as experience is gained. 
Any queries or comments 
on the contents or the use of 
these lists should be addressed 
to herbalmedicines@imb.
ie. The two draft lists can be 
accessed on the IMB’s website 
at www.imb.ie
The IMB launched a public 
consultation process on 
the classification of herbal 
substances in August and the 
date for submissions passed 
on the 30th of September last.
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The national Palliative Medicines Information Service 
recently launched Palliative Meds Info a free medicines 
information helpline service at our Lady’s Hospice and 
Care Services, Harold’s Cross.
The new service aims to encourage best practice 
with medicines in palliative care and to assist health 
professionals in the community, hospitals and 
hospices nationwide by providing specialist up-todate, 
evidence-based information. Palliative Meds Info will 
be the first structured medicines information service 
dedicated to patients needs at end of life and it aims 
to significantly improve quality of care nationally. The 
service is supported by the Irish Hospice Foundation.
‘Getting the dosage right or effectively controlling 
symptoms can be highly complex when dealing 
with end of life patients’, said Mo Flynn, CEo our 
Lady’s Hospice and Care Services. ‘With the launch of 
Palliative Meds Info Service, health professionals who 
previously would not have had ready access to such 
specialist support, can now just phone or email the 
service. our Lady’s Hospice and Care Services always 
strives to be at the forefront in Palliative Care and this 
service is a way in which we can proactively share our 
specialised knowledge with those involved in end of 
life patient care in non specialist settings’, she added.
Palliative Meds Info is an initiative of the pharmacy 
department working in specialist palliative care 
at our Lady’s Hospice, under Veronica Treacy, 
(Superintendant Pharmacist for St James Hospital and 
our Lady’s Hospice and Care Services) and Eimear 
o’Dwyer, Supervising Pharmacist, our Lady’s Hospice 
and Care Services.
The service will operate five days a week and has a 
dedicated phone line and email address for receiving 
queries 01-4912578, palliativemedsinfo@olh.ie
It is aimed at any healthcare professional caring for 
patients with palliative care needs across a range of 
settings, supporting both the palliative care specialist 
and the practitioner who may encounter a patient 
with palliative care needs infrequently, including 
community pharmacists, GPs, public health nurses, 
nursing home staff, hospice and hospital-based 
nurses, doctors and pharmacists.
Palliative Meds Info is to be run as a pilot for the 
next 18 months. All enquiries will be recorded in a 
database to facilitate ongoing audit to ensure the 
service meets the needs of health professionals 
working in palliative care. An analysis of enquiries 
received will also help identify areas of practice where 
further research is required to build on the evidence 
base in palliative medicine.
Good News
for chesty coughs
Exputex™
Carbocisteine mucolytic syrup
COMPLETE WITH
CHILD RESISTANT
TAMPER EVIDENT
CAP
SUGAR FREE
✓ Non drowsy
✓ Mentholated
✓ 300ml - the lowest cost
sugar free carbocisteine
mucolytic syrup (on a ml
per ml basis 250mg/5ml)1
Prescribing Information 
(Please refer to full Summary of Product Characteristics [SmPC])
Exputex 250mg/5ml Oral Solution
Presentation: Carbocisteine provided as 250mg/5ml oral solution.  Uses: As
a mucolytic adjunct for respiratory tract disorders characterised by excessive
or viscous mucous. Dosage and administration: Oral. Adults/Elderly:
Three 5ml spoonfuls three times daily initially. Reduce to two 5ml spoonfuls
three times daily when a satisfactory response has been obtained. Children:
6-12 years: 5ml spoonful (250mg) two to three times daily. 2-5 years: Half a
5ml spoonful (125mg) two to three times daily. Under 2 years: Not recom-
mended.  Contraindications: Hypersensitivity, patients with known active
peptic ulceration.  Special Warnings and Precautions: Patients with a his-
tory of peptic ulceration, avoid in patients with active ulceration, patients on a
controlled sodium diet.  Contains parahydroxybenzoates (E215, E217 and
E219), sunset yellow FCF (E110) and ethanol.  Interactions: None listed.
Pregnancy and Lactation: Not recommended.  Undesirable Effects:
Nausea, headache, gastrointestinal upset and skin rash.  Overdose: No
experience. Serious effects not expected.  Legal category: S1B(E)  Product
Authorisation number: PA 488/14/1. Product Authorisation holder:
Monmouth Pharmaceuticals Limited, Hampshire International Business Park,
Chineham, Basingstoke, Hampshire, RG24 8EP, UK.  Distributed by: Cahill
May Roberts, Pharmapark, Chapelizod, Dublin 20.  Further information is
available from: Shire Pharmaceuticals Limited, Hampshire International
Business Park, Chineham, Basingstoke, Hampshire, RG24 8EP, UK.  Tel: +44
1256 894000. Date of revision: June 2008. Exputex is a registered trade-
mark of Shire US Inc. in Ireland.
Adverse events should be reported to the Pharmacovigilance Unit
at the Irish Medicines Board (IMB) (imbpharmacovigilance@imb.ie).
Information about adverse event reporting can be found on the IMB
website (www.imb.ie). Adverse events may also be reported to
Shire Pharmaceuticals Ltd on +44 1256 894000.
Monmouth Pharmaceuticals Ltd,
Hampshire International Business
Park, Chineham, Basingstoke, Hants
RG24 8EP
MONMOUTH
P H A R M A C E U T I C A L S
1 MIMS May 2008 Date of preparation: October 2008  IRE/EXP/08/0001
Exputex 145x210  16/10/2008  10:51  Page 1
The Centre for Research on occupational and Life 
Stress and School of Psychology at nUI Galway are 
currently recruiting individuals to take part in a study 
which aims to improve understanding of men’s sexual 
problems within Ireland. Men aged 18 years or over, 
both heterosexual and homosexual, are asked to 
participate in the study.
Lorraine McDonagh, a lead researcher on the study, 
said: “Sexual function is strongly associated with 
overall well being and therefore sexual dysfunction 
is an important public health concern. To our 
knowledge, to date, no research has examined 
Irish men’s understanding and experience of 
sexual problems. In addition, previous research 
in this area in other countries has mostly focused 
on heterosexual men. The findings of this project 
should help to inform the development of improved 
health promotion strategies for sexual problems and 
dysfunctions in men”.
Participants need not have personally experienced 
any problems (although personal experience is 
welcome), but be willing to discuss this issue as 
part of a focus group. Those who participate will be 
entered into a prize draw for a "one4All" gift voucher 
worth €100.
For details on how to participate in the study, 
contact the principal investigator Lorraine McDonagh 
at 091-492820 or l.mcdonagh7@nuigalway.ie or the 
study supervisor, Dr Ian Stewart at 091-493569 or ian.
stewart@nuigalway.ie. or log on to www.nuigalway.
ie/crols/participate.html
Men required for sexual 
research study
national Palliative Medicines information service 
Launched at our Lady’s Hospice and Care services
eimear o’Dwyer, Chief Pharmacist, our Lady’s Hospice 
and Care services, Mary Harney, TD, Minister for Health 
and Children, Mo Flynn, Ceo, our Lady’s Hospice and Care 
services; Cliona Hayden, senior Pharmacist.  
32894 Nurofen Pack Trade IrishPhar 340x245.indd   1 30/09/2010   10:38
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1st) 
Marie Donnellan 
2nd)  
orla naughton 
3rd)  
Majella Brady 
Lady captain, anne nolan presenting first prize to Marie 
Donnellan at LPgs outing to adare on 21st august.
Lady Pharmacists 
golf outing august
new edition of 
medicines.ie on CD-RoM 
Pharmacists and dispensing 
doctors across Ireland will now 
be able to order unusual and 
difficult-to-source products 
to help meet specific patient 
needs following the successful 
trial of a new service.
Irish-owned unlicensed 
medicines manufacturer 
The Specials Laboratory is to 
roll out its ‘Special obtains’ 
service nationally, which is 
aimed at assisting pharmacists 
in sourcing items that are 
not regular lines and often 
not stocked by mainline 
wholesalers.
The service, which was 
initially introduced in north 
East England, minimises time 
spent in the dispensary by 
pharmacists trying to track 
down infrequent, low-volume 
and new products that are not 
readily available.
Pharmacists can now 
contact the award-winning 
company to source items 
such as gluten free products, 
colostomy and ostomy lines, 
homeopathics, dressings, 
cover creams and dermatology 
products such as silk vests.
Sharon Griffiths, managing 
director at The Specials 
Laboratory, said: “By 
developing a strong network 
of supply partners, our 
new sourcing service takes 
the hassle out of unusual 
prescription queries and 
eliminates wasted time spent 
by pharmacists on the phone 
searching for such tricky to 
obtain items.
“The initial regional trial we 
carried out has gone well and 
has been very well received by 
pharmacists. Sitting alongside 
our well-established specials 
manufacturing service, we 
hope our new…service will be 
just as successful in helping 
pharmacies meet one-off 
patient needs as quickly as 
possible,” added Sharon.
once a product has been 
sourced by The Specials 
Laboratory, the order is only 
placed once a price is agreed 
with the pharmacist. Special 
obtain orders are delivered 
direct to the pharmacy in 3-5 
days and regular supply for 
repeat prescriptions can also 
be set up.
The Specials Laboratory is 
one of the UK’s leading makers 
of unlicensed medicines – 
known as ‘specials’ – which are 
bespoke-made for individual 
patients and supplied through 
dispensaries. It looks after 
thousands of pharmacy and 
hospital customers across the 
UK and Ireland, delivering 
around 95 per cent of specials 
within 24 hours.
In the last few years, the 
business has also adapted 
to the changing economic 
climate by investing heavily 
in and launching two nHS-
focused services to help 
increase efficiency, reduce cost 
and improve patient care in 
hospitals.
Its over-labelling service 
involves the supply of 
medicines pre-labelled with a 
hospital’s own bespoke design, 
helping hospitals across the 
UK cut down waiting time 
for patients in pressurised 
situations such as out of hours 
dispensing.
More recently, The Specials 
Laboratory was granted 
a license to manufacture 
and supply non-sterile 
investigational medicinal 
products (IMPs) for use in 
small-scale nHS-based clinical 
trials. This allows hospitals 
to outsource their product 
manufacturing needs to help 
speed-up clinical studies and 
ensure medicines are made to 
the highest possible quality 
standards.
owned by United Drug, 
it employs around 135 staff 
across its three MHRA-licensed 
sites, the company was earlier 
this year crowned north East 
Manufacturer of the year and 
north East Company of the 
year across northumberland 
& Tyneside.  www.specialslab.
co.uk
unlicenced medicines 
sourcing service launched
The IPHA has announced the 
release of the medicines.ie 
CD-RoM Version 2010/2011. 
The CD-RoM, which is a 
copy of medicines.ie , is sent 
annually, free of charge, to 
over 7,000 GPs, consultants, 
nurse prescribers, nursing 
homes, community and 
hospital pharmacists in Ireland. 
It is primarily designed for 
those who do not have ready 
internet access in their place 
of work. 
Like medicines.ie the CD-
RoM provides Irish-specific 
and reliable, IMB/EMA 
approved information on over 
2,000 medicines currently 
available in Ireland.
In 2010 medicines.ie was 
certified with the Health on 
the net (Hon) Code Standard 
for Trustworthy Health 
Information. The Hon code 
is the most widely accepted 
reference for online health 
and medical publishers. 
other recent developments 
on medicines.ie include the 
provision of information to 
help people know more about 
medicines and how to manage 
minor ailments. There is also 
a link to a comprehensive 
database listing details of 
both ongoing and completed 
clinical trials, globally.
If any healthcare 
professional has not received a 
copy of the CD-RoM they may 
email communications@ipha.
ie or call (01) 660 33 50 to order 
a copy free of charge.
The potential development 
of a non-antibiotic treatment 
for rosacea; finding out if we 
can manage schizophrenia by 
controlling iron levels in the 
brain; and the identification 
of new therapeutic options 
for patients with chronic 
lung disease, are just some 
examples of research projects 
which have benefitted 
from a new €26 million 
investment programme in 
health research announced 
last month by the Health 
Research Board.
 An additional €12.6 million 
was also announced for a 
new round of funding which 
researchers will be eligible to 
compete for before the end 
of this year.
Announcing the funding at 
the new Convention Centre 
in Dublin, Minister for Health 
Ms Mary Harney said: “I 
anticipate we will see a great 
return on this investment. 
Firstly, this research will 
generate new treatments and 
new ways to care for patients. 
Improving outcomes for 
patients is our primary goal.
“Many of the projects 
will also provide clear 
evidence about changes 
in healthcare practice that 
can create efficiencies and 
help transform the health 
system. This is a welcome, 
timely and important focus 
of HRB funding programmes. 
Importantly, this funding 
will also support jobs, create 
training opportunities or 
develop career paths for 80 
highly skilled people in the 
health sector. It will add to 
the international standing of 
Ireland in health research and 
increase our attractiveness 
as a location for research 
and development in the 
lifesciences.”
According to Enda 
Connolly, Chief Executive 
at the HRB: “we ensure that 
the research we support is 
of the highest quality. But 
it must also be capable of 
being applied in practice 
for maximum benefit to 
the patient and healthcare 
system. This is paramount in 
determining how we allocate 
funding today.”
new €26 million investment programme 
in health research announced
The results of the recent golf outing in Adare Manor were as 
follows:
Please note the following are the officers for the 2011 – 2012 
season:
Lady President: Peggy Fox; Lady Captain: Anne Hillery
Hon. secretary: Ann o'Connor 087 2326483
Competition secretary: Doreen o'Donoghue 086 2336896
Hon Treasurer: Marie Walsh 
Category 1) 
Celeste o'Regan 
Category 2) 
Ann o'Connor
Category 3) 
Helen Grimes
Front 9) 
Anne Murphy
back 9)  
Catherine Cleary
Longest Drive)  
Celeste o'Regan
nearest the Pin) 
Gerarldine Gahan.
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A number of independent 
pharmacists have come 
together to launch a new 
nationwide health management 
service aimed at providing a full 
consultation and management 
of conditions from asthma to 
Alzheimer’s and diabetes to 
weight-loss it was announced 
recently.
More than 20 independent 
pharmacists have joined 
Intervene and 70 more from 
around the country are looking 
to join the group. Intervene is 
the brainchild of independent 
pharmacist Garvan Lynch and 
his co-founder Sheena Lynch. 
They have been running the 
service for the past two years 
out of their pharmacy in the 
Cork suburb of Douglas and are 
now rolling out the programme 
nationally in other independent 
pharmacies.
“Four out of five people 
presenting at a GP consultation 
relate to chronic illness and its 
complications. Chronic illness 
can be treated but not cured 
and the most prevalent of these 
in Ireland include Alzheimer’s, 
diabetes, hypertension, heart 
disease and stroke and are a 
large and growing burden on 
the health of Irish people and 
the Irish healthcare system,” said 
Sheena Lynch.
“Independent pharmacists 
have a huge wealth of 
knowledge that is not being 
used to the best benefit of 
the customer at the moment. 
Intervene changes all of that 
and gives an individual who 
is looking for information, 
treatment and management 
of an illness that is based on 
medical facts access to the 
tools to do so. This works by 
attending an Intervene clinic 
or programme in their local 
independent pharmacist’s 
private consultation room.
“Take diabetes for example 
– if you have been diagnosed 
with diabetes by your GP 
you can now go to your local 
independent pharmacy to 
attend a customised diabetes 
programme that monitors your 
condition and advises you on 
nutrition including diabetic 
menu plans, lifestyle changes 
and exercise activities. you 
will be brought through the 
explanation of what drugs you 
are using and how they help 
and an explanation of what 
exactly the illness is. you will 
then be given a login to the 
‘My Intervene’ section of www.
intervene.ie with a special 
password that is specific to 
information relating to diabetes 
which you can access anytime 
and anywhere,” she said.
Co-founder of Intervene, 
Garvan Lynch said: “People 
need ongoing help in managing 
their conditions. The difference 
with an Intervene Independent 
pharmacy is that you get a 
total health management 
service on your doorstep. GPs 
may diagnose a patient with 
diabetes and then refer them 
to Intervene to manage this. 
Equally, a patient might present 
themselves at an Intervene 
pharmacy undiagnosed and the 
pharmacist will refer them to 
their local GP for diagnosis.
“This relationship is hugely 
important as the medical 
industry working in partnership 
with independent pharmacies 
will only strengthen the health 
management for the patient. 
The range of clinics Intervene 
associates will be able to offer 
will complement GP services. 
The concept will work both 
ways – time-poor GPs will have a 
resource to manage conditions 
and clinics will lead to referrals 
to GPs. We successfully run 
health clinics for men and 
women ranging from epilepsy 
to asthma – ante-natal care to 
medicine use review. "
independent pharmacists launch 
new health management service
only 35 per cent of patients 
use inhalers correctly 
In a recent study of over 1000 
patients, carried out by Hickey's 
Pharmacies, only 35 per cent of 
patients were found to be us-
ing their inhalers correctly. This 
contrasts with 91 per cent of 
respondents who believed they 
were correctly using their inhal-
ers. Following a brief instruc-
tion on inhaler technique by 
their pharmacist, 86 per cent of 
patients were able to demon-
strate correct the correct use of 
their inhaler.
Tom Concannon, Super-
intendent Pharmacist with 
Hickey's Pharmacies and the 
coordinator of the study com-
mented: "At Hickey's Pharma-
cies we are always looking for 
ways to improve the services 
we provide to our patients. The 
Inhaler Technique Assessment 
is a wonderful example of the 
positive effect pharmacists 
can have on how patients take 
their medicines. The drastic 
improvement we were able to 
demonstrate, highlights for us 
the importance of delivering 
more of these types of services 
to our patients in the future." 
This study was carried out 
across the 27 branches of 
Hickey's Pharmacies as part of 
the annual asthma awareness 
campaign. Inhaler users of all 
ages were invited to demon-
strate their inhaler technique 
to a trained member of staff 
who assessed them using a 
standard protocol. Patients had 
the purpose of each of their 
inhalers explained to them and 
any patient who had difficulty 
using their inhaler was given 
a full demonstration. These 
demonstrations were very 
successful as the number of 
patients who could now use 
their inhaler correctly increased 
from 35 per cent to 86 per cent. 
Patients who were still unable 
to use their inhalers were re-
ferred back to their doctor with 
a recommendation to switch to 
a more suitable inhaler. Patients 
who smoked were also offered 
advice on smoking cessation.
The fact that 91  per cent of 
patients thought they were us-
ing their inhaler correctly also 
demonstrates the importance 
of these types of interventions 
by healthcare professionals. It 
is not enough to wait for these 
patients to ask for advice.
Dr Jean Holohan, CEo of 
the Asthma Society of Ireland 
commented on the study 
"The study is a very valuable 
piece of research. It highlights 
a very significant issue in the 
management of asthma. We 
are delighted that Hickey's 
have undertaken this valuable 
research and we encourage all 
patients with asthma to avail 
of the expertise of their local 
pharmacist to get advice on 
inhaler technique.”
only 1 in 7 over 65s has received 
the pneumococcal vaccine
only one in seven people over the age of 65 has been vaccinated 
against pneumococcal disease, leaving approximately 400,000 
people aged 65 and over at risk of contracting the potentially fatal 
disease. This research was undertaken to mark the launch of a 
new website entitled www.oneinseven.ie, which will offer health 
advice for over 65s and information on pneumococcal disease and 
vaccination. The website was developed by Sanofi Pasteur MSD in 
partnership with Age Action.
For further information, visit www.oneinseven.ie
sheena and garvan Lynch Founders of intervene help 
gillian o’ sullivan, Fitness expert(centre), launch 
intervene – ireland’s first health management service 
which is available in independent pharmacies nationwide. 
at the launch of oneinseven.ie were Ms Lisa McLaughlin, 
senior Product Manager, sanofi Pasteur MsD, and irish 
musician and songwriter Phil Coulter.
ABBREVIATED PRESCIBING INFORMATION 
 Presentation: Sachet containing the active ingredients Sodium Chloride 0.47g, Potassium Chloride 0.30g, Glucose 3.56g and Disodium Hydrogen Citrate 0.53g. Indications: Oral correction of fluid and electrolyte loss and the management of watery 
diarrhoea in infants, children and adults. Dosage and Administration: Each sachet should be reconstituted in 200ml (approximately 7 fluid ounces) of fresh drinking water. For infants where fresh drinking water is unavailable the water should be 
freshly boiled and cooled. The solution should be made up immediately before use. If refrigerated, the solution may be stored for up to 24 hours, otherwise any solution remaining an hour after reconstitution should be discarded. The solution must 
not be boiled after reconstitution. Daily intake may be based on a volume of 150ml/kg body weight for infants and 20-40 mg/kg body weight for adults and children. A reasonable approximation is: Infants – One to one and a half times the usual feed 
volume. For infants under 12 months, use only under medical advice. Children – One sachet after every loose motion. Adults (including elderly) – One or two sachets after every loose motion. More may be required initially to ensure early and full volume 
repletion. Contraindications: None known. Warnings and Precautions: The solution must not be reconstituted except with water at the volume stated. Solutions of greater concentration may result in hypernatraemia. Those of greater dilution may 
result in inadequate replacement. If there is no improvement within 24-36 hours, consult the physician. If nausea and vomiting are present with the diarrhoea, small but frequent amounts of dioralyte should be drunk at first. No specific precautions are 
necessary in the elderly. However, caution is required in cases of severe renal or hepatic impairment or other conditions where the normal electrolyte balance may be disturbed. Pregnancy and Lactation: Dioralyte is not contra-indicated in pregnancy 
or lactation. Interactions and Adverse Effects: None stated. Overdose: In the event of significant overdose, serum electrolytes should be evaluated as soon as possible, correct any abnormalities and monitor levels until return to normal, especially 
in the very young and in cases of severe hepatic or renal failure. Precautions for Storage: Do not store above 25°C. The reconstituted solution should be used immediately but may be stored for up to 24 hours in a refrigerator at 2-8°C. Marketing 
Authorisation Holder: sanofi-aventis Ireland Ltd., Citywest Business Campus, Dublin 24. Marketing Authorisation No. PA 540/98/1 (Blackcurrant), PA 540/98/2 (Citrus), PA 540/99/1 (Natural) Legal Category: P Further information: Available from 
sanofi-aventis Ireland Ltd., Citywest Business Campus, Dublin 24 or contact IEmedinfo@sanofi-aventis.com. Please refer to Summary of Product Characteristics which can be found on IPHA @ http://www.medicines.ie/ before prescribing. 
Information about adverse events reporting can be found at www.imb.ie. Adverse events should be reported to the sanofi-aventis Drug Safety Department. 
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Loss of water and 
electrolytes as a result 
of diarrhoea or fever can lead 
to dehydration, particularly 
in children and the elderly. 
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eu news
Gary Finnegan,
European Correspondent and Irish 
winner of the 2009 EU Health Prize 
for Journalists
Community pharmacists have 
saved Finland over €500 
million by cutting medication 
errors and reducing the need 
to consult doctors, according 
to a new study.
Research by 
PricewaterhouseCoopers 
has revealed that a total of 
6.2 million visits to GPs and 
750,000 A&E visits are avoided 
every year thanks to services 
provided by pharmacists. 
The findings, presented 
in Helsinki at the annual 
conference of the International 
Pharmaceutical Federation, 
also show pharmacy expertise 
reduced the need for 
prescriptions by 2.6 million per 
year and saved an estimated 
123,000 hospital bed days. 
The Association of Finnish 
Pharmacists (AFP), which 
helped conduct the study, 
said there is no shortage of 
anecdotes on the economic 
value of community 
pharmacists but this audit of 
health spending in Finland 
adds to the evidence base. 
Erkki Kostiainen of the AFP 
said free professional services 
save the exchequer money 
that can be used elsewhere. 
"We thought that these 
savings would be substantial, 
but it is fair to say that we were 
surprised to find their true 
extent," he said. 
The study drew on the 
research into prescription 
errors and a survey of Finnish 
pharmacists and doctors. 
Statistics from the Finnish 
social insurance and health 
and welfare institutions were 
also examined to help put a 
figure on the savings arising 
from pharmacy services. 
The researchers believe their 
estimates on cost savings, 
which were calculated by 
an expert panel including 
economists and lawyers, are 
conservative. "These savings 
add up to a total of €565 
million per year, which can 
be spent on other important 
priorities in the national 
healthcare system," Kostiainen 
said. 
“The majority of the saving – 
about €300 million – comes 
from fewer visits to GPs. In 
many cases a pharmacist's 
guidance in self-care and 
non-prescription medication 
can be all that is needed and, 
if it is not, pharmacists are able 
to advise when a visit to the 
doctor is indicated," he added. 
Kostiainen said the findings 
could be applicable in 
other countries and will be 
of considerable interest to 
governments in search of 
cost savings. "At a time when 
there are grave shortages of 
general practitioners in some 
European regions, this is not 
simply an economic but also a 
social benefit," he said. 
The study also showed 
savings of nearly €70 million 
in emergency costs, and 
around €100 million each on 
prescription costs and nights 
in hospital.
These total savings are more 
than Finnish pharmacies' share 
of all medicine sales, which 
are around €481 million. 
"This means that savings for 
healthcare produced by the 
use of community pharmacies 
exceed the costs of outpatient 
medicine distribution. This 
is a very significant finding," 
Kostiainen said. 
Ton Hoek, General Secretary 
and CEo of the FIP said 
pharmacists' expertise should 
be used not only for the 
benefit of patients, physicians 
and other healthcare 
professionals, but also to make 
savings in national healthcare 
systems. "now that healthcare 
is becoming more and more 
expensive and there is a 
move towards rationing of 
certain drugs and treatments, 
it is really madness that the 
valuable skills of pharmacists 
are not being used to the 
maximum benefit of patients," 
he said. 
The FIP chief said 
governments should 
encourage people to consult a 
pharmacy before seeing a GP. 
The European Association of 
Hospital Pharmacists (EAHP) 
has pledged to promote global 
coding standards for medical 
products in an effort to 
advance patient safety. 
The Association has 
signed a memorandum of 
understanding with a not-for-
profit standards organisation 
GS1. 
“In hospitals, personalised 
treatments are prepared in 
the pharmacy or ward, and 
administered by nurses to 
the patients. A complete and 
unambiguous identification of 
the drug, up to the moment 
of administration, is a key 
element of a safe dispensing 
procedure when drugs are 
dispensed,” said Roberto 
Frontini, President, of the EAHP. 
“We encourage the adoption 
and harmonisation of GS1 
Standards in Europe to enable 
the effective and efficient 
implementation of bar codes 
on all packages of drugs,” he 
added. 
Frontini said the ultimate 
goal would be a system using 
bar-coded medical products, 
enabled by global standards, 
which would ultimately 
make hospital processes 
more efficient and reduce 
medication errors. 
Hospital pharmacists 
want coding standards
Two-thirds of the patient and 
consumer organisations work-
ing with the European Medi-
cines Agency receive funding 
from the pharmaceutical sector, 
according to health campaign-
ers. 
The regulator's efforts to 
involve independent patient 
groups could be undermined 
by the extent to which they rely 
on industry funds, says Health 
Action International. 
Based on new data on 
financial transparency, the nGo 
said fewer than half of the 23 
organisations working with the 
EMA have complied with the 
Agency's financial reporting 
guidelines. 
HAI is pointing the finger at 
the regulator for failing to rigor-
ously enforce its own guidelines 
at a time when the Agency is 
working to improve transpar-
ency. 
The annual average corpo-
rate contribution per spon-
sored organisation rose from 
€185,500 in 2006, to €282,090 
in 2007, to €321,230 in 2008. 
These amounts correspond to 
47%, 51% and 57% of organisa-
tional average annual revenue, 
respectively. 
"It is to the credit of the regu-
latory process in the EU that the 
EMA has in recent years tried to 
involve patient and consumer 
groups in some aspects of drug 
policy and approval," write Dr 
Graham Dukes of the University 
of oslo and Dr Andrew Herxhe-
imer of the Cochrane Collabora-
tion in the HAI report. 
"But the procedures have to 
be well defined and respected, 
and the consumer groups 
involved must be financially in-
dependent and truly impartial," 
say the authors. 
Patient groups relying 
on industry funding
Pharmacists help cut a&e spending
 Supported by upcoming consumer advertising campaign and in-store promotional material
Cymex Cream has a Triple Action Formula    
    Soothes the tingling sensation.
    Relieves painful chapped lips.
    Controls infection.
issue 9 volume 12 • oCToBeR 2010
16
heRBal mediCine
Dr Des Corrigan is the former 
Director of the School of Pharmacy 
at TCD, and won the Lifetime 
Achievement Award at the 2009 
Pharmacist Awards.
He is the Irish representative 
on the Scientific Committee of 
the European Monitoring Centre 
for Drugs and Drug Addiction. He 
also currently chairs the national 
Advisory Committee on Drugs as 
well as the chair of the Traditional 
Herbal Medicinal Products 
Subcommittee of the Advisory 
Committee on Human Medicines at 
the Irish Medicines Board.dr des CorrIGAN
i
n an earlier column I wrote about my habit, 
whenever I visit a pharmacy, of looking 
to see which herbal products, if any, are 
on sale. I find the fact that a large number 
of herbal sedatives/tranquillisers feature 
prominently on pharmacy shelves to be an 
indication of the high levels of stress, anxiety and 
insomnia which pervades our lives, seemingly 
throughout human existence. one website 
gives an extrapolated figure of 583,000 for those 
with sleep disorders in Ireland while the 2005 
European Working Conditions Survey reported 
that stress at 22 percent was the second most 
common work-related health problem across the 
EU after backache and muscular pain.
Many people respond to these conditions by 
using one of the vast range of highly effective 
benodiazepines and related 'Zed' drugs prescribed 
for the short term relief of anxiety or insomnia 
which are severe and disabling. According to the 
General Population Survey on Drug Use in Ireland, 
conducted by the nACD in 2006/2007, lifetime 
prevalence (i.e. ever having used) for tranquillisers 
was 11 percent of adults while 5 percent had 
used them in the previous year (recent use) and 3 
percent in the past month (current use). 
serious siDe eFFeCTs
This widespread treatment of sleep disturbances 
with synthetic drugs such as benzodiazepines 
is associated with undesirable effects including 
dependency, hangover effects and anterograde 
amnesia according to the European Medicines 
Agency (EMA) Assessment Report on Valerian 
Root. There is also considerable mortality 
associated with the use of synthetic sedatives 
because the national Drug-Related Deaths Index 
(nDRDI) prepared by the Health Research Board 
shows that 37 percent of the 2120 deaths due 
to poisonings recorded in this country between 
1998 and 2007, involved benzodiazepines usually 
in combination with other CnS depressants 
such as alcohol and narcotic analgesics. 
vaLerian rooT
The EMA Report goes on to state that there is 
“obviously a need for better tolerated alternatives 
to synthetic sedatives to prevent…. chronic 
insomnia”. It then points out that a considerable 
number of trials underline that Valerian root is 
such an alternative medication which does not 
show the typical unwanted effects seen during 
conventional treatment of sleep and mood 
disorders. 
The evidence base for efficacy is strongest for 
Valerian but a range of other herbal materials 
have been subjected to scrutiny by the Herbal 
Medicinal Products Committee (HMPC) at the 
EMA. Plants such as Hops, Passiflora and Melissa 
or Lemon Balm are sometimes formulated 
on their own or they may be marketed as 
combinations with Valerian with product names 
highly suggestive of their use as herbal sleeping, 
relaxing or calming agents. The Community 
Monographs published by the EMA following 
detailed assessment of the preclinical and clinical 
evidence on Valerian, Hops, Passiflora and Melissa 
all state that these are traditional herbal medicinal 
products for relief of mild symptoms of mental 
stress and to aid sleep. Crucially the monograph 
on Valerian, under the 'Well-established Use' 
provisions of the basic Medicines Directive, also 
includes a therapeutic indication as a herbal 
medicinal product for the relief of mild nervous 
tension and sleep disorders. The point here is 
that such a claim must be supported by clinical 
trial evidence whereas the traditional use claim 
does not require such evidence but as the 
monograph makes clear, it is “exclusively based on 
long standing use”.
PassiFLora
Passiflora is a popular herbal tranquilliser. The 
EMA concluded that the pharmacological 
and clinical data on Passiflora supported the 
traditional use which is documented back to 1938 
in Europe, but that the clinical trial data was not 
sufficient to designate the herb under 'Well-
established use'. While there are no reported 
side effects there is a warning about driving after 
using it due to its recognized sedative effects. 
MeLissa
In the case of Melissa the assessor noted two 
clinical studies showing clear evidence of a 
sedative effect in healthy volunteers but deemed 
them not acceptable in the context of traditional 
use because the trials used an extract prepared 
with methanol instead of the more usual ethanol-
based liquid extracts and tinctures. This seems 
somewhat pernickety to me. 
HoPs
Ssometimes labeled as Lupulus on products, 
Hops has a long tradition of use but there is very 
little scientific evidence that it is effective as a 
sedative. Most of the data included in the EMA’s 
assessment Report on Hops actually dealt with its 
phytoestrogenic properties.
The evidence relating to Valerian is much 
stronger with sedative effects reported in animal 
studies as well as receptor binding studies which 
point to both sedative and anxiolytic effects 
which appear to be influenced by different 
chemicals from the plant. The clinical evidence 
for relief of sleep disorders is based on several 
randomized placebo-controlled trials (Level 
1B evidence) while the indication for relief of 
nervous tension is based on a lower level (III) 
of evidence from descriptive or comparative 
studies.
Pharmacists should not only have no worries 
that they are recommending any kind of 'quack' 
medicine when they recommend Valerian to 
patients, but they may be doing them a favour 
because valerian does not reduce vigilance the 
next morning unlike Benzo’s and also unlike the 
former it does not act synergistically with alcohol. 
graDuaL onseT
It is important to note that because of the 
gradual onset of improved sleep structure over 
2 to 4 weeks Valerian is not suitable for acute 
episodes of mild nervous tension or sleep 
disorder, so patients will need to be advised 
that it will take a while before they notice 
improvements. But at least colleagues now know 
that there are natural alternatives available to 
them with a PA number signifying a product 
evaluated by the IMB under the well established 
use route. Failing that they should look for (and 
demand from suppliers) a product with a TR 
number indicating registration as a traditional 
herbal product which has been produced under 
GMP conditions and whose quality has been 
rigorously controlled and monitored. With access 
to such products both you and your patients can 
now have a good nights sleep!
While there are no 
reported side 
effects there is a warning 
about driving after using 
[passiflora] due to its 
recognized sedative effects.
There seems to be an 'epidemic' of insomnia in 
Ireland – are herbal remedies the answer ponders 
Des Corrigan
Valeriana officianlis
To sleep,  
perchance to dream
“
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or Professor Peter Weedle, Adjunct 
Professor of Clinical Pharmacy 
at the School of Pharmacy, 
UCC and owner of the Mallow 
based Weedle Pharmacy Group, 
pharmacy has always been a 
family affair. 
Weedle Pharmacy has a long 
and proud tradition of serving the people of 
Mallow, Co Cork. Peter’s maternal grandparents 
Barty and Eily Sullivan established the original 
pharmacy in Mallow in the 1930s and it was 
above this shop that Peter was reared until the 
age of five. 
Despite never knowing his grandfather Barty 
who died in his 40s, Prof Weedle was no doubt 
inspired by him. His aunt Eileen Sullivan, who 
on the death of her father studied pharmacy 
in Dublin and was put through a traditional 
apprenticeship, and his mother nora, a 
dispensing optician, together with their mother 
(Peter's grandmother Eily), and their business 
partner pharmacist Mike Mortell, ran the family 
business. In the 1970s nora, the enterprising 
Corkwoman, opened a second pharmacy in 
Townview in Mallow. 
Today the Mallow based Weedle pharmacies 
are owned by Prof Weedle and the business 
remains very much a family affair, his sister and 
two of her children also work there.
Youngest RegistRaR
Born in Mallow in 1959 Prof Weedle was the 
youngest person ever to be appointed Registrar 
of the PSI in his early 30s and was the founding 
Head of the School of Pharmacy in UCC. He 
was also one of the first Professors of Clinical 
Pharmacy in the country and was instrumental in 
laying the groundwork for the development of 
the 2007 Pharmacy Act.
A keen academic and author, Prof Weedle has 
a Masters in Law and has co authored two books: 
The Law relating to Medicines and Pharmacy in 
Ireland. 1991. Kenlis. (Weedle and Cahill) and 
Pharmacy and Medicines Law in Ireland which he 
co-edited with Ms Leonie Clarke will be published 
early in 2011. He is also the editor of: Medicines: A 
guide for everyone. 9th Edition. 2003. Penguin. (P. 
Parish).
Prof Weedle has also served on the Council of 
the PSI as Chair of the Registration Committee, 
and as a Ministerial appointee.
He also served as a member of the expert 
committee on veterinary vaccines, with the Irish 
Medicines Board and is currently a member of the 
Professional Conduct Committee of the PSI.
Prof Weedle studied pharmacy at the Welsh 
School of Pharmacy in Cardiff in Wales and after 
registration in 1982 he stayed on at the Welsh 
School until 1987. During this time he did a PhD 
on drug use in residential homes for the elderly 
and he also worked as a Research Associate 
under Professor Peter Parish. A medical doctor by 
profession and the first person to be appointed 
Professor of Clinical Pharmacy in the UK, Prof 
Parish proved to be a hugely inspiring mentor to 
the young Peter Weedle.
MentoR
The Cork pharmacist described his time as a 
student in Cardiff as “one of the biggest blessings 
in my life”.
“The School was very forward thinking and had 
appointed the first professor of clinical pharmacy 
in the UK the year I started, Professor Peter Parish, 
who made a significant impact on my thinking. 
Imbued with his vision for the profession I 
decided to return to do a Ph.D. under him in 
clinical practice once I had qualified. So in the 
early 1980s we started looking at the rational use 
of medicines for the elderly in nursing homes. 
once I completed my doctorate I stayed on at the 
school as a research associate for a year.”
In 1987 Prof Weedle returned to Ireland where 
he was appointed as assessor pharmacist at 
the national Drugs Advisory Board (now the 
Irish Medicines Board). Recalling his time at the 
nDAB he said it was “an exciting time” during 
which he was “very privileged to work with some 
exceptional people” under the direction of the 
Chief Pharmacist Dr Mike Morris.
Less than a year later the position of Assistant 
Registrar came up at the PSI and in 1989 the Cork 
pharmacist was successfully appointed to the 
post. In 1990 he was to become the youngest 
person ever to be appointed Registrar of the 
Society, a position he held for two years.
“They are getting older and wiser now,” he 
smiled.
“Joining the Pharmaceutical Society was 
another big change for me but looking back it 
was perhaps one of the most enjoyable times 
of my career. There was an exceptional vision to 
do something; to drive the profession forward 
to deliver pharmaceutical care. The Council 
members at the time were very dedicated 
individuals, and while it would be unfair to 
single out any particular member, I recall being 
astounded by the dedication and selflessness 
of the late Tony Quirke, who after a day’s work 
would drive from Clonmel to attend a committee 
meeting at 8pm in Dublin and often return home 
well after midnight. He did this week in week 
out, right through the autumn/winter/spring, 
sometimes twice a week. I thought, if that is 
the level of devotion being shown by council 
members who weren’t being paid then the least 
I could do was my very best, given that it was my 
job.”
According to Prof Weedle Ireland in the late 
80s and 90s was a very challenging and at times 
frustrating period to be a pharmacist. This, he 
explained, was mainly due to the fact that despite 
In the first of a series of 
articles June Shannon 
speaks to a number of 
pioneering Irish 
pharmacists who have 
made a unique 
contribution to the 
development of 
pharmacy in Ireland.
Masters of Pharmacy
Professor Peter Weedle 
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a number of amendments in 1890, 1908, 1951 
and a major revision in1962, pharmacists were 
still, in essence, operating and registering under 
the hugely outdated and wholly inadequate 
Pharmacy Act of 1875.
“Another major change occurred for me 
when in 1991 Joe Cahill retired as Registrar 
and Secretary of the Pharmaceutical Society. 
I must say I was a reluctant candidate for the 
job as I was very content and challenged in my 
role as assistant registrar, which I was enjoying 
immensely, and to try and fill Joe’s shoes was a 
very daunting challenge.”
FRustRation
“Looking back I think we achieved a lot in the 
PSI during that time, but the biggest frustration 
was not having realised a new Pharmacy Act,” he 
stated.
In 1992 a family illness forced Prof Weedle to 
return to Mallow to take over the running of the 
family business, however he continued to take 
an active interest in the development of the 
profession, and was later to be appointed Chair of 
the PSI’s newly formed Registration Committee in 
anticipation of the new Pharmacy Act of 2007.
“The preliminary work done by the 
committee in the two years prior to the 
Act, which was difficult and complex due to 
the EU requirements, allowed for a smooth 
introduction of the new registration system for 
pharmacists, pharmacies, EU pharmacists and 
overseas pharmacists. It is with a great degree of 
satisfaction that I look back on how effectively 
that team of people worked and what they 
achieved,” he said.
During his time at the PSI Prof Weedle, 
together with a group of highly committed 
pharmacists including the PSI President at the 
time Ms Anne Frankish, Council members Mr 
Ronan Quirke and Mr Mattie Lynch and PSI 
solicitor Mr Dominic Dowling, worked hard 
to put the ground work in place for the new 
2007 Pharmacy Act – arguably one of the most 
important legislative developments in Irish 
pharmacy in the past 130 years.
While Prof Weedle and his many PSI 
colleagues were involved in laying the 
preparatory groundwork for the 2007 Act he 
credited the current Registrar of the PSI Dr 
Ambrose McLoughlin with securing the new 
Act. According to Prof Weedle Dr McLoughlin’s 
appointment as Registrar of the PSI in 2005 
“revolutionised the PSI.”
“I know full well that to this day we still would 
not have a new Act but for Ambrose McLoughlin,” 
Prof Weedle said.
“When Ambrose joined the PSI as registrar 
he very quickly and incisively identified what 
deficiencies were within the profession and 
in particular [he] really knew that unless we 
had a proper regulatory base …pharmacy as a 
profession was not going to develop… Ambrose 
brought a set of skills within the political arena 
and landed us the pharmacy Act 2007,” he added. 
CoRk gene
When Prof Weedle returned to community 
pharmacy in 1992, his Dublin colleagues at the 
time gave him six months before he returned to 
the capital. However being Dubs, his colleagues 
had completely underestimated the strength 
of the legendary Cork homing gene, as Prof 
Weedle went on to become the founding Head of 
Ireland’s newest School of Pharmacy in UCC and 
continues to practise in his native Mallow today.
“I really enjoy community practice, I like the 
contact with people, being part of the local 
community, my family have been in the area for 
hundreds of years so it is truly home for me,” he 
told Irish Pharmacist.
In 1995 Prof Weedle was appointed part-time 
lecturer at the Department of Pharmacology and 
Therapeutics at the School of Medicine in UCC. 
From 2002 to 2003 he served as Acting Head 
of UCC’s fledgling School of Pharmacy, and he 
was also appointed Adjunct Professor of Clinical 
Pharmacy, a position he still holds today.
“In 1995, I was asked by my old friend Prof 
Kamal Sabra to meet Prof Michael Murphy, 
Professor of Pharmacology, School of Medicine, 
UCC (now the President of UCC) to discuss why 
there was no School of Pharmacy in Cork…
Michael said to me ‘Peter you know all the 
reasons why there is no School so how about 
helping me to establish a School?’ That was 15 
years ago and as they say ‘if I knew then what 
I know now, would I do it all over again?’ yes 
most emphatically I would. It was a long drawn 
out process and there were many hurdles to 
overcome and our mantra became ‘it is only a 
matter of time.’ When we got accreditation I was 
presented with a pestle and mortar with that 
motto engraved on it. I had obviously said it far 
too often.”
“The establishment of the School of Pharmacy 
at UCC was a unique experience and a truly 
awesome opportunity. I could never have 
dreamed of becoming Head of a School of 
Pharmacy let alone in my home-place of Cork. I 
was appointed the first Head of School not that 
it was very onerous in that I had no students, 
no staff and no building. I know Prof Caitriona 
o’Driscoll and Prof Anita Maguire have had it far 
tougher than I ever did,” he said.
PhaRMaCY eduCation
“Having three schools of pharmacy and the 
development of pharmacy education over 
the past decade in Ireland has been good for 
the profession. The new graduates are highly 
educated and capable and are a credit to the 
Schools and pharmacy. It gives me great pleasure 
each year to see the new students arrive and 
the final year students graduate. I try not to miss 
any of the graduations. I still get a warm sense 
of pride walking through the main concourse of 
the building, especially late on a winter’s evening 
when it is dark outside and the building is silent 
after the activity of the day. If I was ever to come 
back as a ghost, I think I would wander the 
corridors there,” Prof Weedle added.
According to Prof Weedle the new School of 
Pharmacy at UCC is the only building on the 
historical Cork campus that doesn’t face inwards 
but rather has an entrance onto College Road. 
This was done deliberately he explained as it was 
symbolic of the profession looking forward to the 
future and looking to the public.
The positioning of the new School at UCC 
and Prof Weedle’s deep affinity with it is also 
reflected in his own interest and dedication to 
the development of the pharmacy profession 
into the future.
2020 RePoRt
In 2008 he was asked by the PSI to assist in the 
writing of the landmark Pharmacy 2020 Interim 
Report, in collaboration with Dr Mark Ledwidge, 
Professor Julia Kennedy, Dr Stephen Byrne 
and Dr Laura Sahm from the Clinical Pharmacy 
Practice Research Group at the UCC School of 
Pharmacy and Dr Paul Gallagher from the School 
of Pharmacy at the RCSI.
Published in April 2008 the interim report 
charts a course for the development of 
progressive pharmacy practice and services in 
Ireland.
Entitled 'Advancing Clinical Pharmacy Practice 
to Deliver Better Patient Care and Added Value 
Services' the interim report examines a range 
of measures and options, which through the 
expanded clinical role of pharmacists have a 
real potential to deliver cost effective and high 
quality patient care.
Prof Weedle said he was immensely proud of 
the report particularly as it was written in just a 
number of months and that a lot of hard work 
went into preparing it.
“I still believe that what was outlined in the 
report, given that it was based on international 
evidence of what pharmacists around the world 
were doing, gave a blueprint of what could be 
achieved by Irish pharmacists. The English White 
Paper which was published a few days later 
concurred with a lot of what we said, so we were 
not alone in our ideas,” he stated.
Despite the current economic climate Prof 
Weedle believes that there is still “a great future” 
for pharmacy in Ireland.
“But we have to get out and prove our worth 
to the policy and decision makers. The next few 
months and years present a golden opportunity 
for the profession to rise above the economic 
crisis facing Ireland and prove how we can 
add extra value in healthcare. I don’t think 
pharmacists are trusted by various departments. 
While we 
continue to be 
appreciated by the 
general public, we 
have singularly failed to 
prove our worth in the 
corridors of power.
…the recent 
initiative in 
relation to the codeine 
problem has been seen 
in certain influential 
circles as pharmacists 
stepping up to the 
mark…
“
“
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The next few 
years present a 
golden opportunity 
for the profession 
to rise above the 
economic crisis facing 
Ireland and prove 
how we can add extra 
value in healthcare.
“
Patients beFoRe PRoFit
Government or other professions. While we 
continue to be recognised and appreciated by 
the general public and the patients we serve, 
we have singularly failed to prove our worth in 
the corridors of power; it is no use saying how 
wonderful we are, we have to prove it, over 
and over again before we are accepted. I think 
the recent initiative by the PSI in relation to the 
codeine problem has been a major service to 
patients but it has also been seen in certain 
influential circles as pharmacists stepping up to 
the mark, acting as professionals and not just as 
shopkeepers taking a profit. In essence they are 
truly putting – “patients before profit”. I know this 
may be controversial, but I am sure this will open 
up more opportunities for us to demonstrate 
our unique value to Society and will be another 
defining moment in our profession.”
Coupled with his work with UCC, the PSI and 
running two busy pharmacies Prof Weedle 
somehow has also found time to develop a 
new company called Pharmacy Prime with 
pharmacist colleagues Mr norman niven and 
Dr Mark Ledwidge. Pharmacy Prime provides 
independent community pharmacists with 
a suite of services that they can offer to their 
patients and nursing homes.
“ I keep on threatening my wife that I will 
take it easier, that I will stop getting involved 
in new projects, that I will take up walking and 
gardening again, both of which were passions 
of mine. As soon as a project is completed I 
declare that is it; I’m not going to get involved 
again, but she just looks at me knowing full well 
that it won’t be long before I’m off again…we 
have five children who are our pride and joy, our 
eldest graduated last year and he is working in 
Dublin, the next two are both at university and 
the youngest two are at school, our last Junior 
certificate is next summer. our greatest joy is our 
granddaughter Lauren and we love it when she 
visits us for a sleep-over.”
adviCe FoR the Young
Asked what one piece of advice he would give to 
young people thinking of entering the profession 
Prof Weedle said it was to think of pharmacy as a 
vocation rather than a job or a career.
“If you think pharmacy is an easy job with lots 
of money, it isn’t. If it is done right it is hard and 
demanding, but extremely satisfying in being 
able to help people. Pharmacists can make 
a significant contribution to the health and 
wellbeing of their patients but if they are careless 
or incompetent that can cause major damage, or 
death, to patients, so do not enter the profession 
casually. It is not a job or a career but a vocation.”
“Community pharmacists are a vital part of 
their local communities, I am dismayed by some 
of the developments in pharmacy in recent 
decades, in my grandfather’s day the community 
pharmacist was a pivotal focus for healthcare 
in the community. I think we have lost that, to a 
degree we have become more product focussed 
instead of patient focussed. As community 
pharmacists we forget on a day-to-day basis the 
impact we have, for good or bad, on patients. 
What we do is important, we impact on patient’s 
health, and we are a key part of the care of 
patients. We are privileged to hold a unique 
position of trust and we must never abuse this for 
our own gain. We like everyone else in Ireland got 
caught up in the ‘Celtic tiger’ era, it is now time 
for us to re-focus, return to our roots and build 
from there,” he concluded. 
Qualifications
Hold a Minimum B.Sc. (Pharmacy) Candidates 
must be registered or entitled to register with 
the Pharmaceutical Society of Ireland and/or The 
Royal Pharmaceutical Society of Great Britain. A 
postgraduate Diploma/MSc in Clinical Pharmacy or 
higher is desirable but not essential. 
experience
• Candidate must have gained a minimum of three 
years experience working in Hospital Pharmacy/
Community Pharmacy at a senior level.
• Candidate will ideally have a good understanding 
of Pharmacy within both the nHS and HSE 
healthcare systems.
• A thorough understanding of current IT systems 
being applied within Pharmacy both the HSE and 
HSE is desirable.
• Candidates should be able to demonstrate 
methodical and accurately work practices.
• Have excellent interpersonal skills as well as been 
a team player.
• Demonstrate a thorough understanding of 
inappropriate prescribing and the StoppStart 
Criteria
role/responsibility
• The successful candidate will be responsible for 
the following
• All aspects of Compliance and Validation and 
monitoring of new IT systems developed.
•  The writing of all relevant policy and procedures 
and validation protocols pertinent to the position.
• The validation process and outcome analysis of 
the IT systems.
• Liaising with the inventors of StoppStart.
• Ensures that the Drug to Drug and Drug to Disease 
interactions are in full compliance within the IT 
system.
• The transfer of technology and support 
documentation from the inventors in UCC to the 
company.
• Develops a strong working relationship with the 
advisory board and UCC.
• Co-ordinates trials with various healthcare 
providers.
• Take full responsibility for all Regulatory/
Compliance/Quality/Accreditation including ISo 
13485.
• Guide and direct all employees on all clinical 
matters.
• Take full responsibility for Research and 
Development and the release of all new products.
• Work closely with all other departments to ensure 
company goals and objectives are achieved.
• Research the entry requirements to new markets.
• Represents the company at medical conferences 
and presents papers at same.
• Develops a strong working relationship with all 
customers.
• Prepare monthly safety and compliance reports. 
• Ensures new product pipeline objectives are 
achieved.
• Undertakes assignments as assigned by 
management.
• Takes full responsibility for department budget. 
Clinical support information systems Ltd®
Clinical support information systems Ltd. Head-quartered at the national Technology Park Limerick Ireland. Csis is dedicated to becoming the leading 
International Software Provider to address the problems associated with Inappropriate Prescribing of drugs in the elderly. This innovative IT tool will Alert 
Clinicians to appropriate pharmacotherapies. Inappropriate prescribing is an internationally accepted problem that exists within healthcare systems.
This is a unique opportunity to join a new Start Up Company 
all C.v’s to gpmoran@coolmeen.com
Position Chief scientific officer
Back
Arenathe
in
Clonmel Healthcare has signifi cantly reduced the 
prices of its generic prescription branded medicines 
and continues to offer savings to healthcare 
professionals and patients alike.
Trusted partner with over 40 years healthcare experience in Ireland
Extensive product range including single source offerings for niche therapy areas
Fastest growing Top 10 OTC healthcare company in Ireland. Ref: IMS June 2010
2010/ADV/GEN/097
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QuesTions & answeRs
tom murrAy
What is your greatest fear?
That anything bad would happen to any of my 
four kids.
When and where were you happiest?
I am usually pretty happy, and acknowledge 
how lucky I am to be able to say that. I try to 
find some happiness every day, but any time I 
am having fun with my wife Róisín and kids and 
forgetting about work or any other stresses is 
hard to beat.
What would your super power be?
Mind control.
 
What is the worst job you have ever done?
Checking sewerage systems when I worked on 
the buildings in my late teens.
What is your best trait?
Haven’t a clue, you would need to ask others.
What is your most unappealing habit?
Pigheadedness, and a failure to see other 
people’s point of view.
 
What trait do you most dislike in others?
Dishonesty and sycophantism.
Do you use alternative medicines? What kind? 
yes I shower every day so that takes care of 
homeopathy, and I drink good Irish whiskey so 
that naturally brings stress relief.
Cat or dog?
Dog, no question.
What keeps you awake at night?
Everything, I tend to replay the day in my mind at 
night, and I usually only get a few hours sleep as a 
result.
Who or what makes you laugh?
Good comedy, my kids, friends, some of the 
characters I meet each day at work. There is 
usually at least one funny point in each day.
How do you relax?
I coach hurling, gaelic football and I read and 
play some music. I also write a bit of poetry and 
I have started writing a few novels on several 
occasions but don’t have the self discipline to 
finish, or I realise that if it is boring me, then why 
the hell would anyone else read it. 
What word or phrase do you overuse?
It isn’t printable, unfortunately I can be emotive 
in my expression, let’s just leave it at that.
Favourite Tv/radio programme?
Rónán Beo, ar RnaG idir 3 agus 5 gan aon dabht 
ar bith.
Favourite film and book?
Film: The Field or anything with Morgan 
Freeman. Books: nineteen Acres or Rothar Mór 
an tSaol.
sporting hero/heroine and why?
DJ Carey, he wasn’t huge but he never shirked 
his responsibility on the field and he also did 
some amazing trickery that made my hair stand 
on end.
What is your motto?
Everyone is equal and should be treated that 
way. And if you are afraid of something then you 
must do it.
How would you like to be remembered?
In different ways by different people, by my wife 
and kids as a loving husband/parent, by others 
as an interesting person who was true to himself 
and by everyone as a good laugh.
Tom was born in 1973 in Coventry. His mother is from galway and 
his father from Mayo. He was educated at Princethorpe College and 
later at Manchester university. after his Prereg he did a Masters 
through Queens university belfast. His thesis was based on patients' 
acceptability of extended pharmacists’ roles. While in the uK he was 
a keen member of Local Pharmacy Committee, where contractual 
issues were decided, etc. 
Tom moved home to ireland and bought his pharmacy in 
november 2001, opening a second outlet in november 2005. He has 
been a member of iPu committees, firstly as alternate to his good 
friend Joe britton. More recently he was active within PCC and other 
union subcommittees. He has retired from committees for now due 
to too many time constraints. He is married for thirteen years and has 
four children.
What other career might you have chosen?
not sure, I chose to become a pharmacist at 
16 because I had done work experience in a 
pharmacy and I really believed I could make a 
difference to people. I also believe a community 
pharmacist is in the centre of the local 
community and becomes naturally involved with 
their patients. I still believe that the pharmacist 
has the potential to have a huge impact on those 
they serve. Having said that other careers interest 
me, I love marine biology and would love to be 
involved in marine life conservation projects, 
especially the larger marine mammals.
Which figures in irish life (living or dead) do you 
admire and why? 
There are many, and my personal political beliefs 
have been framed by many of Ireland’s greats. 
I admire anyone who acts with integrity and is 
prepared to act in a manner consistent with his 
convictions. I don’t admire anyone who operates 
double standards or who professes one thing 
but acts in an entirely different way. Be true to 
yourself before you try to convince others. 
What is the one thing you would suggest to 
improve the irish health service?
I would remove the two tier access to healthcare 
and make it fair for all. Far too often that we read 
health statistics about the probability of illness in 
certain demographics, and yet they are often the 
very people who cannot get access to treatment 
because of financial factors. And of course I 
would radically change the pharmacist’s role. 
I believe the role of diagnosis and prescribing 
should be separated and that prescribing 
pharmacists working along with doctors would 
ensure the maximum benefits for patients as the 
expertise of both parties would be brought to 
bear. Radical and probably impossible to achieve.
What is your earliest memory?
 I think it was when I was around 3, playing in the 
garden with my brother and my Dad.
EYELIDS
WRINKLES 
BAGS &
DARK CIRCLES
RoC® SUBLIME ENERGY™ EYE
Electro-stimulation, for the first time in a cream.*
Visible anti-ageing results in just 3 hours.**
Inspired by electro-stimulation, a professional anti-ageing treatment, RoC®
creates a breakthrough in skincare. New RoC® Sublime EnergyTM Eye with
e-pulseTM  technology, combines a unique concentrate with an activating
moisturiser to stimulate the skin’s repair systems***. The appearance of
wrinkles, puffiness and dark circles are visibly reduced. In just 3 hours,
get anti-ageing results that our other eye creams give in 4 weeks**.
*from RoC,** clinical evaluation, 26 subjects, ***in-vitro
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leTTeRs To The ediToR
when recovering from the flu you 
may not be getting all the vitamins and 
minerals you need to aid a speedy recovery
metatone for use after illness, colds or flu, when 
feeling tired or run down and after loss of appetite
metatone - just the tonic  
Licensed Medicine. Always read the leaflet.
Further information available on request.
Chefaro Ireland Limited, Farnham Drive, Finglas, Dublin 11, Ireland.
Tel: 01 879 0647      E-mail: info@omega-pharma.ie
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Dear Madam,
“It is not the strongest species that 
survive, nor the most intelligent, but 
the ones who are most responsive to 
change” Charles Darwin
Health services worldwide face the chal-
lenge of meeting ever-increasing demand 
within finite resources. As well as develop-
ing new services, consideration must be 
given to how existing services will be 
delivered. Simply maintaining the status 
quo – doing things the way they always 
have been done – is not going to be an 
acceptable strategy for any health service. 
Change is inevitable.
Likewise, all healthcare professions are 
also facing change at an unprecedented 
rate. We need to challenge our own think-
ing and ensure we are truly meeting our 
patients’ needs. Pharmacists have always 
been at the heart of the communities they 
serve. We understand how customers’ 
needs change and the need for constant 
innovation.
But, it has to be expected that as phar-
macists develop their skills to deliver more 
services to patients, there will be some 
challenge, both from within and without 
the profession. This is evident from some 
of the comments which appeared [in last 
month's issue (page 8)]. There is always 
resistance to change, and there is nothing 
new in doubts being expressed about 
competence or qualifications when one 
healthcare profession expands its role into 
what is seen as the territory of another. 
Indeed, there can often be internal resist-
ance to broadening of responsibilities 
from within the profession itself.
To meet this challenge, leaders within 
the profession must articulate an over-
arching vision of the future for pharmacy 
and put in place the tools needed for it 
to succeed. The pharmacist’s role has 
changed significantly in many countries. 
The provision of flu vaccinations is a good 
example of this. What is currently seen as 
innovative for Boots in Ireland is already 
the norm in the US and Portugal.
our vaccination service also shows how 
we support our pharmacists to develop 
themselves to take on new roles.
First, we have a robust risk manage-
ment process in place. All our clinical 
services are under the professional direc-
tion of the superintendent pharmacist, 
supported by clinical governance proc-
esses and standard operating procedures. 
In addition, the flu service is overseen by 
the company’s medical director. our clini-
cal services are subject to rigorous internal 
audit and meet all external regulatory 
requirements.
Then, for all Boots pharmacists deliver-
ing enhanced services, there is extensive 
additional training. This covers clinical 
knowledge, practical skills (including 
administration of the vaccine, resuscita-
tion and managing adverse events), and 
personal skills, such as change manage-
ment and counselling skills.
To witness the enthusiasm and profes-
sionalism of Boots pharmacists during 
recent training events was uplifting. They 
are confident that they are fully trained 
and competent to deliver the flu vaccina-
tion service.
We know, too, that public perceptions 
of pharmacy are changing. Extensive 
customer research and focus groups has 
revealed an overwhelming demand for 
more services to be provided by pharma-
cists. Boots is responding to this demand 
and we will listen closely to our customers 
as we continue to develop services that 
meet their needs.
I am heartened by the many conver-
sations I have had with other leaders 
in pharmacy and healthcare in Ireland 
recently. I believe that there is a consensus 
that pharmacy practice must, and will, 
change to really deliver patient benefits, 
building on our traditional role as experts 
in medicines.
I urge pharmacists, and other health 
care professionals, to look forward not 
back: see what might be possible, not the 
hurdles that must be cleared, and engage 
in real collaboration to deliver better care 
to patients in a cost-effective way.
We need more leaders and advocates 
for pharmacy with a vision and passion to 
deliver – not more naysayers!
Mary rose burke, Chief Pharmacist, 
boots ireland.
“Pharmacists should know 
their place” – doctors react to 
recent developments at boots
Letters to the editor:
email: maura@
greencrosspublishing.ie
Post: 
The Editor
Irish Pharmacist
7 Adelaide Court
Adelaide Road
Dublin 2
Fax:  
01 4789449
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NEW ClonMedica’s new Lactease Infant Drops is leaving babies with colic speechless. And their parents.
 Lactease is from ClonMedica and we’ve 
got over 20 years’ experience in the use 
of lactase enzyme. So it’s no surprise that it 
works.
 The real surprise is that it o
 ers 
astounding value compared to other 
infant drops. And that’s good news for you 
and for your customers. 
New product launch for
Lactease Infant Drops includes:
 National Radio
 National Press
 Web on-line activity
 Shelf unit display
 Shelf talkers
 Public Relations activity
 Window display
Painful colic may be caused by a baby’s inability to break down the lactose in breast milk and infant formula. But just a few 
drops of new Lactease will break down the lactose, making it more digestible.
The
surprising thing is 
not how effective it is.
It’s the price.
Read the package leaflet carefully before use.  Keep out of reach and sight of children.  Contains lactase enzyme and glycerine.
Clonmel Healthcare Ltd. 2010/ADV/LAC/032
TRAD_032Lactease(F)IP_4_'10.indd   1 14/04/2010   13:00:35
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the CoAlfACeopinion
dAvId jordAN
David Jordan has worked 
in community pharmacy 
since 1979, qualifying as 
a pharmacist in 1983. He 
was chairperson of the 
Community Employee 
Committee of the IPU from 
1990 to 1998 and treasurer 
from 1994 to 1996. His 
main stress relief is riding 
his motorbike with his 
friends from 
www.irishbikerforum.com
T
ake Ambrose's letter in relation 
to companies conducting retail 
pharmacy business. It is a wonderful 
statement of the regulations and the 
PSI's interpretation of them but like 
many of Ambrose's pronouncements 
it seems disconnected from the real world. It is 
truly a laudable thing that the regulations state 
that every pharmacy must have a supervising and 
superintendent pharmacist. But what happens 
if our supervising/superintendent pharmacist 
while jogging/cycling/driving to work in their 
pharmacy is hit by the proverbial bus and killed. 
Is that pharmacy supposed to close until the 
board of the company meets and appoints a new 
supervising/superintendent pharmacist AnD 
notifies the PSI of the new appointment? yes 
according to Ambrose's letter. 
All this presumes that the advertising of the 
position, interview and completion of notice 
period in a previous employment can all happen 
in an instant. And woe betide us if all this 
happens on a weekend or bank holiday. I won't 
even go into what happens to patients who 
have left in prescriptions the previous day for 
later collection or methadone patients calling in 
for their daily dose. Then I thought about how I 
would handle this situation and I realized that I 
would not be dealing with this situation. 
one Man banD
Like many of you reading this I am the 
superintendent and supervising pharmacist for 
my own company. I own the company 100% 
and my current wife and myself are the only 
directors. I will be the one hit by the proverbial 
bus. My current wife/future widow will be the 
one dealing with this. So in the midst of her 
(hoped for) grief she will have to go searching 
for a superintendent and supervising pharmacist 
before she even looks for an undertaker. Do all 
this before she sticks me in a box and pops me in 
the oven. It looks like the PSI would be after her 
for their pound of flesh faster than a banker after 
a government guarantee. 
This is classic bully behaviour, huff and puff 
and threaten but don't actually do anything. 
I would love to see them try to prosecute a 
widow(er) in court under these regulations. not 
for the sake of the widow(er) but just to see a 
case hardened judge rip them apart. 
It occurred to me that similar situations arise 
on a regular basis. Last summer in the interests 
of domestic harmony we had a family holiday. I 
secured the services of a good locum and we set 
off. For the next two weeks I was out of contact. 
Mobile phone reception was patchy at best. 
(As an aside how did we manage in the days 
before mobile phones. yes children there was 
such a time). So for two weeks my pharmacy 
was effectively without a superintendent or 
supervising pharmacist. So from a professional 
point of view what is the difference between a 
superintendent pharmacist dead for two weeks 
and the same superintendent incommunicado 
for 2 weeks. Either the legislation and regulations 
were badly drafted by somebody badly advised 
about the realities of real life pharmacy practice 
or it was deliberately drafted this way to have a 
go at pharmacists who would stand up to the 
Minister and the HSE.
If Ambrose thinks that this is unreasonable 
and not the intention of the regulations then all 
it might take is a piece of common sense, (sadly 
lacking it seems in the PSI) and an explanatory 
note covering these type of situations. It may be 
that Ambrose has a S.o.P for this kind of situation 
and if so why not publish it? Has he approached 
the Department of Health seeking a change 
in the law or regulations? or maybe he plans 
to allow for the regulations to be ignored on a 
case by case basis, sitting on high like the Lord 
of Shrewsbury dispensing his munificence to 
those he deems worthy. It could be that he sees 
monsters lurking behind every possible breach 
or challenge to the regulations. If you grow up in 
a land of monsters and train as a monster slayer 
it is not surprising that you treat anybody who 
disagrees with you as a monster. However, this 
is not always the case. Some of them may be 
your allies and only become monsters because 
of how you treat them. A wonderful self-fulfilling 
prophecy. 
It looks like you are damned if you die, damned 
if you don't.
PLain engLisH PLea
As a follow up to a previous article I note that the 
Medical Council has written to Mary Harney to 
warn that patients are at risk of serious medical 
mistakes because EU workforce rules mean that 
doctors from the EU do not need to pass English 
language exams to work in this country. This 
is exactly the same situation as the PSI faces 
with pharmacists from within the EU. Wouldn't 
it be nice if the PSI were to write to Minister 
Harney and ask her to deal with this as a matter 
of urgency that the IMC seems to think that it 
deserves. 
In a previous article I remarked that the 
Pharmacy Journal seems to be getting lighter 
with every issue. It was subsequently pointed out 
to me that there no longer seems to be a letters 
page. Is this because nobody bothers to write or 
was there an editorial decision taken to exclude 
them. Either way it has the effect of making 
the Journal a propaganda piece. And as such it 
becomes less and less relevant to the practising 
pharmacist. 
I didn’t want another 
rant about the PSI but...
they just keep giving David Jordan ammunition
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D
uring the economic boom we 
experienced during the last 
decade many pharmacists 
expanded their businesses. There 
are two ways that any business 
can grow: one method is so-called 
organic growth whereby a pharmacist identifies 
a new or existing community where a need for a 
new pharmacy exists. The would be pharmacist 
then opens a new shop, usually after signing 
a lease and borrowing funds from a bank for 
working capital and other necessities. 
The second method is by acquiring an existing 
successful pharmacy. When a pharmacist invests 
in a business by buying it they would usually 
take over the lease on the premises if it was not 
already owned by the pharmacy business being 
acquired. This process of growth has resulted in 
groups of pharmacists owning small and medium 
size chains of pharmacies most of which have 
leases to be paid at the end of each month.
exaMineR Calling?
As we all know difficulties have arisen in our 
economy which are affecting all businesses 
dreadfully and pharmacy is no exception. Many 
enterprising pharmacists who expanded during 
our economic boom now find themselves with 
falling cashflows for a combination of reasons. 
The cost of the leases does not always fall back 
in line with the new cashflow levels available 
to the business. This imbalance creates huge 
pressure on a business and many chains of retail 
businesses in all areas of the economy are facing 
into examinership. This is a process where the 
arrangements and commitments of a business 
are examined under Court protection to see if 
a struggling business can be saved from being 
put into liquidation. The cost of leases and the 
pharmacist's legal commitment to them has to 
be examined due to the fact that proportionally 
they are so expensive they cannot be ignored in 
an economic downturn.
RePudiation oF leases
Recently the Supreme Court overturned Mr 
Justice McGovern's decision in the Linen 
Supply of Ireland examinership that the current 
legislation does not permit the repudiation of 
leases in an examinership. Before the Supreme 
Court made this ruling it was understood that 
the law did not allow commercial tenants to 
break a lease or significantly adjust the terms. 
The case has now been remitted back to the 
High Court to consider whether, in the specific 
case before it, the leases ought to be repudiated 
in order for a scheme of arrangement to be 
formulated. Schemes of arrangement are very 
useful in addressing the issues and realities which 
businesses in cashflow difficulties face.
When a lease is not a ContRaCt
The Supreme Court held that Section 20 of the 
Companies (Amendment) Act, 1990 should be 
interpreted in the ordinary meaning and that the 
word contract must be interpreted to include 
leases. The court said that leases are, as a matter 
of law, contracts. There are certain basic elements 
of a contract. An offer must have been made and 
an acceptance agreed. A contract must contain 
what lawyers call consideration, which is a 
benefit to each party (this is usually money). And 
finally, the agreement must be one intended to 
have legal meaning and significance. Therefore, if 
a lease does not contain one of these elements it 
cannot be enforced by the law.
In light of the challenges facing the Irish retail 
market, the importance of this decision cannot 
be overstated. It is generally acknowledged that 
examinership is an effective restructuring model 
for a retail business and this of course includes 
pharmacists. The ability to repudiate leases of 
non performing stores is often an important 
part of the process and key to attracting fresh 
investment. The recent High Court decision in 
the o'Brien's Irish Sandwich Bars examinership 
had cast doubt on the ability to repudiate leases 
where agreement could not be reached with 
landlords. 
For the landlord community this decision 
provides little comfort other than some clarity as 
to their negotiating strength in an examinership. 
The key message for landlords is clear: find 
out the financial position of the tenant in 
examinership (and, in particular, the profitability 
of that outlet); assess your leverage and be 
ready to negotiate with the examiner early in the 
process. 
WelCoMe develoPMents?
While the Linen Supply of Ireland case is back 
before the High Court to adjudicate on whether 
the repudiations of leases in this restructuring 
should be permitted, this Supreme Court 
decision will be very much welcomed by the 
restructuring community and any pharmacy 
businesses which find themselves a victim of the 
economic downturn.
When is a lease 
a contract?
...if a lease does 
not contain one 
of the four elements 
[of a contract] it cannot 
be enforced by the law.
Cormac O'Neill discusses the implications for lease 
law after the recent Supreme Court ruling which 
overturned Mr Justice McGovern's decision in the 
Linen Supply of Ireland examinership.
CormAC o’NeIll
Cormac o’neill is a barrister 
practising on the Dublin 
and South Western circuits. 
He is also a chartered 
management accountant 
with considerable 
experience in industry 
and banking. In addition, 
Cormac lectures on 
Business and Law in the 
Institute of Technology 
in Tralee and can be 
contacted on 087 657 1124.
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If only I could 
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Communication is important1-3
Abbreviated Prescribing Information: 
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tion: Pregnancy: Memantine should not be used in pregnant women unless clearly necessary. Lactation: Memantine should not 
be used in women who are breastfeeding. Special Warnings and Precautions for use: Caution is recommended in patients with 
epilepsy. Caution is advised in patients with raised urine pH as this may elevate plasma levels. Clinical trial data are limited on pa-
tients with recent myocardial infarction, uncompensated congestive heart failure and uncontrolled hypertension and patients with 
these conditions should be closely supervised. Avoid concomitant use of NMDA antagonists (see also interactions). Patients with 
sugar intolerance should not take Ebixa. Patients should be warned to take special care if driving and using machines as Ebixa has 
minor to moderate infl uence on these tasks.  Interactions: Effects of L-Dopa, dopaminergic agonists and anticholinergics may be 
enhanced. Effects of barbiturates and neuroleptics may be reduced. Concomitant administration of Ebixa with antispasmodic agents 
e.g. dantrolene and baclofen can modify their effects, dose adjustments may be necessary. Plasma levels of cimetidine, ranitidine, 
procainamide, quinidine, quinine and nicotine may be increased.  Co-administration with hydrochlorothiazide (HCT) may lead to a 
reduced serum level of HCT. Concomitant use of NMDA antagonist- amantadine, ketamine, dextromethorphan or phenytoin should 
be avoided. Close monitoring of prothrombin time or INR is advisable for patients treated concomitantly with oral anticoagulants. 
Adverse reactions: Common (≥1/100 to <1/10) headache, somnolence, hypertension, constipation, dizziness, dyspnoea and drug 
hypersensitivity. Uncommon reactions (≥1/1000 to <1/100): cardiac failure, fatigue, fungal infections, confusion, hallucinations 
(mainly in severe Alzheimer’s disease), venous thrombosis/thromboembolism, vomiting, gait abnormal. Very rare (<1/10,000): sei-
zures. Not known: Isolated cases of pancreatitis and psychotic reactions have been reported post-marketing.  Alzheimer’s disease 
has been associated with depression, suicidal ideation and suicide. In post-marketing experience these events have been reported 
in patients treated with memantine. Overdose: Symptomatic treatment. Elimination: Mainly in unchanged form via the kidneys. 
Legal Category: POM.  Marketing Authorisation Holder: H.Lundbeck A/S, 9 Ottiliavej, DK-2500, Valby, Denmark. Marketing 
Authorisation Numbers: EU/1/02/219/005 Ebixa 10mg/g Oral drops solution-50g bottle. EU/1/02/219/006 Ebixa 10mg/g Oral 
drops solution-100g bottle. EU/1/02/219/007 Ebixa Tablets 10mg, 28 pack size. EU/1/02/219/008 Ebixa Tablets 10mg, 56 pack size. 
Further information may be obtained from: Lundbeck (Ireland) Ltd., 7 Riverwalk, Citywest Business Campus, Citywest, Dublin 24.
Date of Preparation: June 2010
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n late June 1988 we came to Dublin looking for 
work. Joe rented a bedsit in Upper Eccles Street. 
on the outside it was an old Victorian house, 
run down with the chipped red brick, but on 
the inside it was like some sort of unwashed 
web. I saw all the post boxes in the hall and 
wondered how could you get so many individual 
bedsits into one place? Well the answer is you could, 
it just depended on how you wanted to do it.
number 56, Eccles Street had four floors, 16 
bedsits and three toilets that worked. It had a fourth 
on the top floor but the water pressure was too weak 
to get up so basically it wouldn’t flush. The second 
floor had two showers. That was an impossible 
situation if I ever saw one. Everybody wanted a 
shower but nobody wanted to go first as that meant 
paying the meter. 
Ireland was in a serious recession in those days. 
There was a family on the first floor. I think they were 
called the o’Callahgans. Above them and beside us 
was a trainee guard. He’d shower late, maybe after 
ten or so before his night shift. Point is that’s when 
you’d hear the o’Callaghans showering. There’d be 
some heat left over.
For four weeks we walked every street in Dublin’s 
centre but there was no work. The rent was 30 
pounds a week and we took turns on the floor. After 
a month we were down about 180 pounds. It doesn’t 
sound like much and it wasn’t but the lack of any 
employment at all was what worried us. A queue 
of crushed hope at the street’s bottom would form 
every Thursday morning. It had an unwashed look 
about it though the people were clean.
‘That’s going to be us if we’re not careful.’ Joe 
rubbed the dust from his hands.
I’d just got a job delivering ‘The Dublin news’. It 
sounds simple but you try carrying a few hundred of 
those for a few days. There’s a temptation to dump 
them but I didn’t. But then I had the first pay check 
and my first interaction with Mr Whyte.
‘So and so never got his so I’m cutting you a day 
on account of Pearse Street.’
It was bullshit but you couldn’t argue. you could 
forego the day’s wage or argue and forego the rest. 
Four ten pound notes, that’s all was it. But it was the 
stolen ten that burnt the gut. We weren’t qualified 
for anything so there was no point. That night we 
went to the Stag’s Head.
I’d never had a pint before. I mean I’d got drunk a 
few times with Joe on tins of beer or with stolen gin 
from the drinks cabinet. Guinness has a sombre look 
but it’s solid and all there. I used to love the adverts 
for it. The penguin exclaiming
‘My Goodness! My Guinness!’
It took me ages to get that. It’s one of those drinks 
that every first sup reminds you of the first time you 
ever felt the black.
The Dublin news expanded into a few more 
streets and so got Joe a job there. I made the mistake 
of telling Whyte he was with me as opposed to just 
telling Joe to apply straight and see if there was any 
work? Whyte gave Joe the job he would have given 
to whomever but made out it was a favour to me and 
so we both took a reduction. 
‘I haven’t really got the work but seeing as he’s a 
friend I’ll do you a favour. I’ll have to take some off 
though. you know how it is.’
So ten pounds became eight but the way he 
expected us to see it was collectively we got more. It 
was crap but what could you do? 
over the next few weeks we delivered papers 
during the day and at night went to the Stags. I got 
to like the place. The wood was polished from the 
million elbows that had rested there and hanging 
over all with its years of seen wisdom lay the Stag’s 
head. We took to getting drunk there a few times. 
Summer was hot in Dublin that year. you’d come out 
and the midnight air would just hang there. It would 
be dusty what with the heat but there was a sense 
of freedom about it. Joe met a girl there one night. I 
forget her name but met her the next morning in the 
bedsit. She was somewhat English and her voice had 
a clipped but fresh taste about it.
‘Cup of tea? Joe told me a bit about you. Good to 
meet.’ 
I don’t remember much about her except that she 
had a friend called Shelly and that she’d be going 
to the Stag’s again and would I be there? It was a 
probably just throwaway on her part but it felt good.
Sure it was sweet but we were eating through our 
money and Joe was getting restless. one morning 
Whyte really got to Joe. I can’t recall exactly but it 
was probably just his attitude. He collected a double 
load and threw them in the Liffey just at the start of 
the South Dock. They may have been paper but they 
dropped straight down and didn’t float.
‘I don’t know about you Dude, but I’m getting out 
of here.’ He said.
We went to the Stags that night for the last time.
A new street phone had been put outside the 
bedsit. It took those new 50 pence coins, the ones 
with the seven sides. officially Dublin was a 1000 
years old in 1988. It certainly looked and felt every 
year of it. Joe spent a few hours one evening just 
ringing friends in the States. Twice I had to go and 
get more change. They were expensive calls. Joe 
came out of the phone box and just said it.
‘How would you like to be an illegal?’
He said a friend knew some guy called norman 
from new Hampshire that had work in his motel. 
He was based in a beach town called Taunton. We’d 
booked tickets by the week’s end. I had to buy a 
return to fool immigration. 
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ACTOS: Actos 15mg tablets containing 15mg pioglitazone as
hydrochloride - blister packs of 28 EU/1/00/150/001 €39.50. Actos
30mg tablets containing 30mg pioglitazone as hydrochloride - blister
packs of 28 EU/1/00/150/004 €58.75. Actos 45mg tablets containing
45mg pioglitazone as hydrochloride - blister packs of 28
EU/1/00/150/012 €60.52. Indications: Monotherapy treatment of Type
2 diabetes mellitus in patients inadequately controlled by diet and
exercise for whom metformin is inappropriate because of
contraindications or intolerance. As dual oral therapy in patients with
insufficient glycaemic control despite maximal tolerated dose of oral
monotherapy, in combination with either metformin (particularly in
overweight patients) or a sulphonylurea (in patients for whom
metformin is not tolerated or contraindicated). As triple oral therapy
with metformin and a sulphonylurea in patients (particularly overweight
patients) with insufficient glycaemic control despite dual oral therapy.
In combination with insulin in patients with insufficient glycaemic
control on insulin for whom metformin is not tolerated or
contraindicated. Dosage: 15mg or 30mg once daily with or without
food. Dose may be increased in increments up to 45mg once daily. In
combination therapy with insulin the current insulin dose can be
continued. If patients report hypoglycaemia, the dose of insulin should
be decreased. Elderly & renal impairment (Cl creatinine > 4
ml/min): No dosage adjustment required. No information is available
from dialysed patients therefore pioglitazone should not be used.
Children and adolescents (under 18 years): Not recommended.
Contraindications: Hepatic impairment. Hypersensitivity. Cardiac failure
or history of cardiac failure (NYHA stages I to IV). Diabetic
ketoacidosis. Warnings and precautions: Can cause fluid retention,
which may exacerbate or precipitate heart failure. Observe patients for
signs and symptoms of heart failure, weight gain or oedema
particularly those with reduced cardiac reserve or on insulin.
Discontinue pioglitazone if deterioration in cardiac status occurs. For
patients with at least one risk factor for congestive heart failure, start
therapy with the lowest dose of pioglitazone and increase gradually.
Concomitant insulin administration may increase the risk of oedema.
Check liver enzymes before starting treatment. Following initiation it is
recommended that liver enzymes be monitored periodically based on
clinical judgement. Do not start treatment in patients with increased
baseline liver enzyme levels (ALT > 2.5 x upper limit of normal [ULN]).
If ALT levels increase to 3 x ULN, reassess as soon as possible. If ALT
levels remain > 3 x ULN or jaundice is observed, discontinue therapy.
If symptoms suggest hepatic dysfunction, check liver enzymes. Advise
patients to adhere strictly to a calorie-controlled diet and monitor
weight. In some cases, an increase in weight may be a symptom of
cardiac failure. Small reductions in haemoglobin and haematocrit,
consistent with haemodilution have been noted. Treatment in patients
with polycystic ovarian syndrome may result in ovulation. If a patient
wishes to become pregnant or if pregnancy occurs, discontinue
treatment. An increased incidence in bone fractures in women has
been observed in a pooled analysis of safety data involving
pioglitazone treatment. The risk of fractures should be considered in
the long term care of women treated with pioglitazone. Interactions:
Use with caution during concomitant administration of cytochrome
P450 2C8 inhibitors (e.g. gemfibrozil) or inducers (e.g. rifampicin).
Monitor glycaemic control. Pregnancy and lactation: Do not use.
Potential risk unknown. Undesirable effects: Suspected adverse
reactions reported as more than an isolated case in double-blind
studies listed below. Very common: >10%, common: 1-10%,
uncommon: 0.1-1%, rare: 0.01-0.1% and very rare: < 0.01%. In
monotherapy: Common: visual disturbance, upper respiratory tract
infection, weight increased, hypoaesthesia. Uncommon: sinusitis,
insomnia. With metformin: Common: anaemia, weight increased,
headache, visual disturbance, arthralgia, haematuria, erectile
dysfunction. Uncommon: flatulence. With sulphonylurea: Common:
weight increased, dizziness, flatulence. Uncommon: glycosuria,
hypoglycaemia, increased lactic dehydrogenase, appetite increased,
headache, vertigo, visual disturbance, sweating, proteinuria, fatigue.
With metformin and sulphonylurea: Very common: hypoglycaemia.
Common: weight increased, blood creatinine phosphokinase
increased, arthralgia. With insulin: Very common: oedema. Common:
hypoglycaemia, bronchitis, weight increase, back pain, arthralgia,
dyspnoea, heart failure. Oedema reported in 6-9% of patients on
pioglitazone over one year, compared to 2-5% in the comparator
groups (metformin and sulphonylurea). Oedema was generally mild-
moderate and usually did not require discontinuation of treatment. In
most clinical trials, reduced total plasma triglycerides and free fatty
acids, and increased HDL-cholesterol levels were seen, with small, but
not clinically significant, increases in LDL-cholesterol levels. In clinical
trials the incidence of elevations of ALT > 3 x ULN was equal to
placebo. In an outcome study of patients with prior major
macrovascular disease, the incidence of heart failure was 1.6% higher
with pioglitazone than with placebo, when added to therapy that
included insulin. However, this did not lead to an increase in mortality.
Rare cases of elevated liver enzymes and hepatocellular dysfunction
have occurred in post-marketing experience, although causal
relationship has not been established. There have been a small
number of post marketing reports of macular oedema. Be alert for
disturbances in visual acuity. An increased incidence in bone fractures
in women has been observed in a pooled analysis of safety data
involving pioglitazone treatment. Available only on prescription. 
PI Date: Mar 2009. PI code: AC090454. Legal category: POM.
MARKETING AUTHORISATION HOLDER: Takeda Global R & D
Centre (Europe) Limited. Takeda UK Ltd. is responsible for the sale
and supply of ACTOS and COMPETACT in Ireland. ACTOS and
COMPETACT are registered trademarks owned by Takeda
Pharmaceutical Company Ltd. For further information contact: Takeda
UK Ltd. Takeda House, Mercury Park, Wycombe Lane, Wooburn
Green, High Wycombe, Bucks HP10 0HH. Tel: +44(0) 1628- 537900,
Fax: +44(0) 1628-526617.
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Pioglitazone: the facts
ADVERTISING FEATURE
Pioglitazone and durable glycaemic control: the facts
A key clinical aim for patients with Type 2 diabetes (T2D) is to achieve and maintain glycaemic control in order to reduce the risk of important
microvascular and macrovascular complications.1 Insulin resistance is a core defect of T2D and the primary action of the thiazolidinediones (TZDs) is to
increase the sensitivity of tissues to insulin, providing durable glycaemic control.1 In an RCT versus gliclazide, pioglitazone demonstrated long-term
glycaemic control over two years whilst gliclazide showed a marked loss of control after initial short-term gains.2 In addition, pioglitazone therapy was
associated with a lower risk of hypoglycaemia than gliclazide.3
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Pioglitazone and NICE: the facts
NICE endorses a clear place in therapy for pioglitazone post-metformin and in preference to an SU in patients with a significant risk of hypoglycaemia or
its consequences and in preference to a DPP-4 inhibitor where there is marked insulin insensitivity.4 Since it has been shown that 92% patients with T2D
have insulin resistance, a large proportion of T2D patients are suitable for a TZD.5
Pioglitazone and CV outcomes evidence: the facts
In a meta-analysis of over 16,000 uncontrolled patients with T2D, pioglitazone showed an 18% RRR compared with control for a composite of ischaemic
CV risk of all-cause mortality, MI and stroke.6 Although there was an increased incidence of heart failure in the study, this was not associated with an
increased risk of mortality and the authors stated these findings suggest that‘the net clinical CV benefit with pioglitazone therapy is favorable, with an
important reduction in irreversible ischemic events that is not attenuated by the risk of more frequent heart failure complications’.
Pioglitazone is tried and tested: the facts
There are over 12.5 million patient-years experience with pioglitazone since its global launch in 1999.8 It has been extensively studied with
41 randomised, double-blinded, placebo or active-controlled trials in over 20,000 patients with varying degrees of disease severity.6
TZDs can cause fluid retention – reported in 6-9% of patients treated with
pioglitazone for one year in controlled clinical trials – which may
exacerbate or precipitate heart failure. Therefore TZDs have always been
contraindicated in patients with a history, or at any stage of heart failure
(NYHA I to IV).7 Patients should be observed for signs and symptoms of
heart failure, weight gain or oedema particularly those with reduced cardiac
reserve and those already on insulin.7
Meta-analysis included data from 19 clinical trials, of short and long duration, in patients with
uncontrolled Type 2 diabetes (n=16,390). Despite an increased incidence of heart failure in this
study, this was not associated with an increased risk of mortality. RRR = Relative Risk
Reduction. Control = comparator therapies or placebo.
Lincoff AM et al. JAMA, 2007
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Adapted from Belcher et al. Diabetes Res Clin Pract 2005; 70: 53-62
Patients with Type 2 diabetes were randomised to gliclazide (n=297) or Actos (n=270). 127 patients from the gliclazide group and 147 patients from the Actos group completed the study. Primary
analysis was the time to failure to maintain glycaemic control (HbA1c <8.0%). A greater proportion of patients failed to achieve HbA1c <8.0% with gliclazide compared to Actos (Log-rank Test:
p<0.0001). Baseline HbA1c levels were similar for both groups, ranging from 8.5% to 9%. NE = not evaluated.
Adapted from Tan MH et al, Diab Care 2005
AB100728s September 2010 Prescribing Information and References can be found on adjacent page.
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Prescribing Information
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ACTOS: Actos 15mg tablets containing 15mg pioglitazone as
hydrochloride - blister packs of 28 EU/1/00/150/001 €39.50. Actos
30mg tablets containing 30mg pioglitazone as hydrochloride - blister
packs of 28 EU/1/00/150/004 €58.75. Actos 45mg tablets containing
45mg pioglitazone as hydrochloride - blister packs of 28
EU/1/00/150/012 €60.52. Indications: Monotherapy treatment of Type
2 diabetes mellitus in patients inadequately controlled by diet and
exercise for whom metformin is inappropriate because of
contraindications or intolerance. As dual oral therapy in patients with
insufficient glycaemic control despite maximal tolerated dose of oral
monotherapy, in combination with either metformin (particularly in
overweight patients) or a sulphonylurea (in patients for whom
metformin is not tolerated or contraindicated). As triple oral therapy
with metformin and a sulphonylurea in patients (particularly overweight
patients) with insufficient glycaemic control despite dual oral therapy.
In combination with insulin in patients with insufficient glycaemic
control on insulin for whom metformin is not tolerated or
contraindicated. Dosage: 15mg or 30mg once daily with or without
food. Dose may be increased in increments up to 45mg once daily. In
combination therapy with insulin the current insulin dose can be
continued. If patients report hypoglycaemia, the dose of insulin should
be decreased. Elderly & renal impairment (Cl creatinine > 4
ml/min): No dosage adjustment required. No information is available
from dialysed patients therefore pioglitazone should not be used.
Children and adolescents (under 18 years): Not recommended.
Contraindications: Hepatic impairment. Hypersensitivity. Cardiac failure
or history of cardiac failure (NYHA stages I to IV). Diabetic
ketoacidosis. Warnings and precautions: Can cause fluid retention,
which may exacerbate or precipitate heart failure. Observe patients for
signs and symptoms of heart failure, weight gain or oedema
particularly those with reduced cardiac reserve or on insulin.
Discontinue pioglitazone if deterioration in cardiac status occurs. For
patients with at least one risk factor for congestive heart failure, start
therapy with the lowest dose of pioglitazone and increase gradually.
Concomitant insulin administration may increase the risk of oedema.
Check liver enzymes before starting treatment. Following initiation it is
recommended that liver enzymes be monitored periodically based on
clinical judgement. Do not start treatment in patients with increased
baseline liver enzyme levels (ALT > 2.5 x upper limit of normal [ULN]).
If ALT levels increase to 3 x ULN, reassess as soon as possible. If ALT
levels remain > 3 x ULN or jaundice is observed, discontinue therapy.
If symptoms suggest hepatic dysfunction, check liver enzymes. Advise
patients to adhere strictly to a calorie-controlled diet and monitor
weight. In some cases, an increase in weight may be a symptom of
cardiac failure. Small reductions in haemoglobin and haematocrit,
consistent with haemodilution have been noted. Treatment in patients
with polycystic ovarian syndrome may result in ovulation. If a patient
wishes to become pregnant or if pregnancy occurs, discontinue
treatment. An increased incidence in bone fractures in women has
been observed in a pooled analysis of safety data involving
pioglitazone treatment. The risk of fractures should be considered in
the long term care of women treated with pioglitazone. Interactions:
Use with caution during concomitant administration of cytochrome
P450 2C8 inhibitors (e.g. gemfibrozil) or inducers (e.g. rifampicin).
Monitor glycaemic control. Pregnancy and lactation: Do not use.
Potential risk unknown. Undesirable effects: Suspected adverse
reactions reported as more than an isolated case in double-blind
studies listed below. Very common: >10%, common: 1-10%,
uncommon: 0.1-1%, rare: 0.01-0.1% and very rare: < 0.01%. In
monotherapy: Common: visual disturbance, upper respiratory tract
infection, weight increased, hypoaesthesia. Uncommon: sinusitis,
insomnia. With metformin: Common: anaemia, weight increased,
headache, visual disturbance, arthralgia, haematuria, erectile
dysfunction. Uncommon: flatulence. With sulphonylurea: Common:
weight increased, dizziness, flatulence. Uncommon: glycosuria,
hypoglycaemia, increased lactic dehydrogenase, appetite increased,
headache, vertigo, visual disturbance, sweating, proteinuria, fatigue.
With metformin and sulphonylurea: Very common: hypoglycaemia.
Common: weight increased, blood creatinine phosphokinase
increased, arthralgia. With insulin: Very common: oedema. Common:
hypoglycaemia, bronchitis, weight increase, back pain, arthralgia,
dyspnoea, heart failure. Oedema reported in 6-9% of patients on
pioglitazone over one year, compared to 2-5% in the comparator
groups (metformin and sulphonylurea). Oedema was generally mild-
moderate and usually did not require discontinuation of treatment. In
most clinical trials, reduced total plasma triglycerides and free fatty
acids, and increased HDL-cholesterol levels were seen, with small, but
not clinically significant, increases in LDL-cholesterol levels. In clinical
trials the incidence of elevations of ALT > 3 x ULN was equal to
placebo. In an outcome study of patients with prior major
macrovascular disease, the incidence of heart failure was 1.6% higher
with pioglitazone than with placebo, when added to therapy that
included insulin. However, this did not lead to an increase in mortality.
Rare cases of elevated liver enzymes and hepatocellular dysfunction
have occurred in post-marketing experience, although causal
relationship has not been established. There have been a small
number of post marketing reports of macular oedema. Be alert for
disturbances in visual acuity. An increased incidence in bone fractures
in women has been observed in a pooled analysis of safety data
involving pioglitazone treatment. Available only on prescription. 
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terry mAGuIre
T
here is once again hope, as there 
always has been, that developing 
primary care structures will make 
greater use of pharmacists’ skills 
and in doing so improve patient 
care. With breakneck speed 
Primary Care Cooperatives (or are they to be 
called Primary Care Partnerships) – a new form 
of GP fund-holding – is emerging in northern 
Ireland and promising to make more use of 
pharmacy. Budgets for primary care will be 
administered by or through these new bodies 
who will act as providers of services rather 
than commissioners, the commissioning role 
remaining with the Health and Social Care 
Board and the Local Commissioning Groups. All 
very promising indeed but I’m not clear where 
these GP structures came from. They were 
never discussed or debated at the meetings 
of the local commissioning groups; we were 
merely told about them. They offer, as has long 
been the aspiration of all pharmacists, a more 
equitable role for pharmacists in the provision 
of primary care services but the question is will 
they? Perhaps before we get carried away with 
ourselves we need to remember who we are and 
where we are in the bigger scheme of things 
medical. Community pharmacists need to be 
clear that compared to GPs, they are and always 
will be lesser beings and we need to know our 
place.
over the years I have foolishly attempted 
to foster, through equity, better relations with 
GPs with a view of improving patient care and I 
have been singularly unsuccessful. on one 
occasion ringing a GP about his patient whose 
diabetes was totally out of control I was warned 
to mind my own business. This was not the only 
slight. GPs have mostly treated me – properly 
I now think – with silent contempt or explicit 
aggression. other pharmacy colleagues have 
been more insightful about our position in the 
primary care hierarchy and have avoided such 
impertinence and now I am learning to be more 
careful with this important business relationship. 
I need to be more grateful for anything I get from 
general practice.
tRansgRessions
For example last Friday I should never have 
refused that request. oK, it was 5.55 p.m. 
and I was preparing to go on holiday, in five 
minutes I smugly thought soon I would be 
free. The telephone rang “surgery here, I have a 
prescription to telephone through”.
Giving the patient’s name and address the 
receptionist asked that I supply “20 diazepam 
5 mg tablets 1 p.r.n.” and she finished off her 
request with “and that’s for delivery”. now 
I should not have taken exception at the 
statement “and that’s for delivery”. It was not of 
any consequence that this problem patient lives 
in a flat complex that is difficult to access and is 
some distance from the pharmacy. yes in refusing 
to do this delivery I did apologise but I have no 
right to refuse, I should know my place. So it 
was only proper that the receptionist snapped 
back “forget it I’ll telephone it through to Boots”. 
That’ll teach me. 
And then there was my gross incompetence 
when I failed to send a GP practice a batch of 
stamped addressed envelopes. Telephoned 
prescriptions had not been sent for about 
three months. When I telephoned to ask why 
I was abruptly told that they had no stamped 
addressed envelopes left. Had they ask me for 
stamped addressed envelopes? no one knew but 
they were not sending out the scripts until they 
got stamped addressed envelopes! It is of no 
consequence that I was allowing them to retain 
on their books a very lucrative ill patient who 
lives many miles from the practice.
And I should never have refused to telephone 
the surgery. The family of a 94 year old women 
arrived in the pharmacy. They had submitted a 
urine sample to the GP and now that it had been 
analysed the GP was prescribing an antibiotic 
but the GP’s receptionist would not telephone 
the medicine through she insisted the pharmacy 
telephone and request it. And so I should.
"tRade" onlY
Talk of equality is fine but in reality there is a need 
for pharmacists to remember that GPs are atop of 
the primary care hierarchy. To gain the respect of 
GPs I must remain a sycophant. In a radio debate 
some years ago a local GP representative of the 
British Medical Association referred to me as “a 
purveyor of hot water-bottles”. I did not retaliate; 
how dare I and we need these timely reminders 
that in the pecking order we are pretty far down. 
Talk of a greater role for pharmacy will merely 
bring us contempt. What we do is we deliver 
medicines to patient’s doors at inconvenient 
times, we supply stamped addressed envelops 
and we telephone through when it should be 
the other way around. For GPs we are not fellow 
professionals, to them we are trade, we have 
customers not patients, we focus on the business 
not on the professional. Since this is the order of 
things it is highly unlikely that GPs will have much 
of a role for community pharmacy in their new 
structures. Having kept us in our proper place 
they will keep services for themselves.
With recent changes in the structure of primary care 
services in northern Ireland there is a suggestion 
that finally the community pharmacist may become 
an important member of the primary care team. 
Terry Maguire is ever so grateful.
 gPs and us – 
there is a definite 
pecking order
GPs have 
mostly treated 
me – properly I now 
think – with silent 
contempt or explicit 
aggression.
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20 mg & 40 mg gastro-resistant capsules, hard
Esomeprazole
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Nexazole: for the treatment of erosive reflux oesophagitis
Prescribing Information for Nexazole 20 mg & 40 mg gastro – resistant capsules, hard. Qualitative and Quantitative Composition: Each 
capsule contains 20 mg or 40 mg of esomeprazole (as esomeprazole magnesium dihydrate).  Pharmaceutical Form: Hard, gastro-resistant 
capsule: Slightly pink body and cap, containing white to almost white pellets. Therapeutic Indications: Treatment of erosive reflux oesophagitis. 
Prevention of relapse of healed oesophagitis in long-term management of patients. Symptomatic treatment of gastroesophageal reflux disease 
(GERD). Eradication of H. pylori concurrently given with appropriate antibiotic therapy for treatment of H.pylori-associated ulcers. Treatment of 
NSAID-associated gastric and duodenal ulcers in patients requiring continued NSAID-treatment. Prophylaxis of NSAID-associated gastric ulcers 
and duodenal ulcers in patients at risk requiring continued therapy. Prolonged treatment after i.v. induced prevention of rebleeding of peptic ulcers. 
Treatment of Zollinger Ellison Syndrome. Dosage and Method of Administration: Capsules should be swallowed whole with liquid. The capsules 
can be opened and the pellets mixed in half a glass of non-carbonated water or if desired this solution administered through a gastric – tube in 
patients with swallowing difficulties. The capsules and / or contents should not be chewed or crushed. Treatment of erosive reflux oesophagitis: 
40 mg once daily for 4 weeks. Long-term management of patients with healed oesophagitis to prevent relapse: 20 mg once daily. Symptomatic 
treatment of gastroesophageal reflux disease: 20 mg once daily. Eradication of H. pylori for treatment of  H.pylori-associated ulcers: 20 mg with 1 
g amoxicillin + 500 mg clarithromycin, all twice daily for 7 days. NSAID associated gastric & duodenal ulcers: 20 mg once daily for 4 – 8 weeks. 
Prophylaxis treatment: 20 mg once daily. Prolonged treatment after i.v induced prevention of rebleeding of peptic ulcers: 40 mg once daily for 4 
weeks. Zollinger Ellison Syndrome: Initial dose is 40 mg once daily. Dosage should be individually adjusted. Daily doses up to 160 mg have been 
used. If the required daily dose exceeds 80 mg, it should be divided and given twice daily. Severe liver impairment: Patients should not exceed a 
max. dose of 20 mg.  Contraindications: Hypersensitivity to esomeprazole or to any of the excipients. Esomeprazole should not be administered 
with atazanavir. Pregnancy and breast-feeding due to insufficient data. Children under 12 years. Special warnings and precautions for use: The 
possibility of a malignant gastric tumour should be excluded as Nexazole may alleviate symptoms and delay diagnosis. Regularly monitor patients 
on long-term treatment. Patients on on-demand treatment should contact their physician if symptoms change in character. If esomeprazole is 
used in combination with antibiotics, then the instructions for the use of these antibiotics should also be followed. Treatment with esomeprazole 
may lead to slightly increased risk of gastrointestinal infections such as Salmonella and Campylobacter. Contains sucrose – Patients with rare 
hereditary problems of fructose intolerance, glucose – galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine. 
Drug Interactions: Esomeprazole can affect the absorption of ketoconazole and itracanazole. Dose reduction may be required when administered 
with drugs metabolised by CYP2C19 as esomeprazole may increase their plasma concentration.  Monitor patients when given in combination with 
warfarin or other coumarine derivatives. Undesirable effects: Common: Headache, abdominal pain, constipation, diarrhoea, flatulence, nausea/
vomiting. Shelf Life: 2 years. Marketing Authorisation Holder: Pinewood Laboratories Ltd., Ballymacarbry, Clonmel, Co. Tipperary. Marketing 
Authorisation Holder Number(s): PA 281/146/1-2. This medicine is a prescription only product. Further prescribing information is available on 
request. Date of revision of text: July 2010.
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W
hile in a meeting with a 
client recently, he asked the 
question about whether a 
double dip recession was 
on the cards in the US and 
the impact that would 
have on his business here in Ireland. As I don’t 
read the papers or listen to the radio as part 
of my forced sabbatical from all things bad, I 
thought I would need to look abroad for some 
inspiring thoughts before I came back with an 
answer. Low and behold, good economic news, 
although hard to come by lately, is alive and well 
(almost). The essence of what I have endeavored 
to put together it that although the recovery is 
tortoise-like in its movement it does appear to be 
gathering some momentum. 
FaRMing a ReCoveRY
of all the industries affected by the recession US 
agriculture remains relatively resilient as prices 
soar for everything from meat to grains, mostly on 
demand from markets overseas. American farmers 
will export $107.5 billion in agricultural products 
the fiscal year that ended on 30th September – the 
second highest ever after the 2008 record of $115.3 
billion, according to the the new york Times reported, 
citing federal estimates of farm trade and income. 
Asia, and especially China, has driven much of US 
agricultural exports. China is expected to surpass 
Mexico next year as the second-largest foreign buyer 
of American farm products after Canada.
If we could translate this into an Irish economic 
activity then it must heighten our need to refocus 
on our agricultural activities as part of our own 
sustainable recovery. I work with a client who 
specializes in livestock and he says demand for 
Irish livestock is very strong given our quality and 
traceability. 
CoMPanY aCquisition aCtivitY
Last month was the busiest August on record 
for mergers and acquisitions volume worldwide, 
and the $286 billion worth of deals announced 
marked the highest monthly level since July 2008, 
according to Dealogic. The activity was driven by 
companies in sectors ranging from technology 
to agriculture. This included BHP Billiton's (nySE: 
BHP – news) unsolicited $43.4 billion bid for 
Potash (nySE: PoT – news), as well as Intel's 
(nasdaq: InTL – news) $7.7 billion bid for McAfee 
(nySE: MFE – news). And Sanofi-Aventis's (nySE: 
Sny – news) $18.5 billion offer for Genzyme 
(nasdaq: GEnZ – news) on August 29 raised the 
total value of global hostile bids to date to $133.8 
billion, a 26.6% increase over the previous year. 
These are staggering numbers when added 
to the fact that the worldwide level of merger 
and acquisition activity now stands at $1.8 
trillion so far in 2010, up 24% from the previous 
year during the same time. one of the most 
interesting aspects about the peaked activity is 
that the value of deals in Europe and Asia rose 
this year, but the number of deals in each region 
was unchanged. With the recent announcement 
of the sale of the AIB Polish subsidiary for €2.5 
billion, we are likely to see further activity in 
Ireland. A concern within the banking sector will 
be the rise in unemployment this may cause, but 
it might also allow the banks to heal and help to 
stimulate the economy. 
CaR sales
An incredible statistic in Ireland is that new car 
sales here are 49.6% up from 2009 to 2010 to date 
and up 109.65% for the month of August. The car 
industry has long been a barometer on a nation's 
economy; booming in the good times and the 
forefront of a bust when things turn south. Long 
may we see good news here and indeed, as a 
friend of mine in the industry commented, there 
is a shortage of good quality second had cars 
available at the moment. 
It isn’t just in Ireland, but if we look at the home 
of the automobile, Detroit, some interesting 
numbers are also appearing. Ford churned more 
money in the first six months of this year than 
in the previous five years combined. GM, which 
received a $50 billion taxpayer bailout following 
its bankruptcy in June 2009, has filed for one of 
the biggest public stock offerings in US history. 
And Chrysler is hiring new workers. These are big 
turnarounds. The worst clearly isn't over yet but 
these are notable bright spots.
ManuFaCtuRing gRoWth
While the naysayers were predicting in the 
manufacturing output by American factories 
in August, the opposite was true. U.S. 
manufacturing expanded faster than expected 
as factories added workers and raised production 
to restock inventory and respond to demands 
form markets overseas. The Institute for Supply 
Management's factory index rose to a three-
month high of 56.3 from 55.5 in July. Most 
economists predicted it would fall to 52.8 or 
worse. A reading of more than 50 generally 
signals growth. Caterpillar (nySE: CAT – news), 
the Peoria, Ill.-based maker of construction and 
mining equipment, has announced it may add up 
to 9,000 workers globally this year. A stock to buy 
perhaps
Manufacturing, which accounts for about 
11% of the U.S. economy, helped pull the nation 
out of the recession. While Ireland isn’t at the 
forefront of manufacturing, I did come across 
an interesting piece of information on the CIA 
website about Ireland which stated what we 
held 2nd place in the world for consumer price 
deflation of – 4.5%. Qatar holds top spot with – 
4.9% (2009 statistics). So I guess that we can hold 
our head high in at least one area of economic 
fact. 
In all seriousness, this same website noted 
that the amount of foreign direct investment 
company value held in Ireland is estimated at 
€195.2 billion at the end of 2009. now that is 
number worth being aware of in an Irish context.
And the good 
news is....
The omens of recovery are few and far between but 
iain Cahill remains upbeat.
The amount of 
foreign direct 
investment company 
value held in Ireland was 
estimated at €195 billion 
at the end of 2009.
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Nasobec Allergy contains Beclometasone Dipropionate
Offer your customers great value on their 
Beclometasone Nasal Spray with 
New  Nasobec Allergy
Hayfever season…
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Because congestion can impact your 
patients with allergic rhinitis any time of year... 
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NASONEX 50 micrograms/actuation Nasal Spray, Suspension
ABBREVIATED PRESCRIBING INFORMATION [Phenylethyl alcohol-free formulation] Refer to Summary of Product Characteristics 
before prescribing. PRESENTATION: Nasal spray suspension containing mometasone furoate (as monohydrate) 50 micrograms/
actuation, a synthetic topical corticosteroid. USES: Adults and children aged 18 and over: Treatment of nasal polyps. Adults and 
children over the age of 12 years: For the treatment of the symptoms of seasonal allergic rhinitis or perennial rhinitis. Children 6 to 
11 years of age: For the treatment of the symptoms of seasonal allergic rhinitis or perennial allergic rhinitis. In patients who have a 
history of moderate to severe symptoms of seasonal allergic rhinitis, prophylactic treatment with Nasonex may be initiated up to four 
weeks prior to the anticipated start of the pollen season. DOSAGE: Nasal Polyposis: Adults and children aged 18 and over: The usual 
recommended starting dose for polyposis is two actuations (50 micrograms/actuation) in each nostril once daily (total daily dose of 
200 micrograms). If after 5 to 6 weeks symptoms are inadequately controlled, the dose may be increased to a daily dose of two sprays 
in each nostril twice daily (total daily dose of 400 micrograms). The dose should be reduced following control of symptoms.  If no 
improvement in symptoms is seen after 5 to 6 weeks of twice daily administration, alternative therapies should be considered. Efficacy 
and safety studies of Nasonex Nasal Spray for the treatment of nasal polyposis were four months in duration. Seasonal or Perennial 
Allergic Rhinitis: Adults and children over the age of 12 years: Two sprays (50 micrograms/spray) in each nostril once daily (total dose 
200 micrograms). Once symptoms are controlled, dose reduction to one spray in each nostril (total dose 100 micrograms) may be 
effective for maintenance. If symptoms are inadequately controlled, the dose may be increased to a maximum daily dose of four sprays 
in each nostril (total dose 400 micrograms). Dose reduction is recommended following control of symptoms. Children 6 to 11 years of 
age: One spray (50 micrograms/spray) in each nostril once daily (total dose 100 micrograms). Clinically significant onset of action 
occurs in some patients within 12 hours after the first dose. Full benefit of treatment may not be achieved in the first 48 hours. Regular 
use is recommended to achieve full therapeutic benefit. CONTRAINDICATIONS: Hypersensitivity to any of the ingredients. Do not use 
in the presence of untreated localised infection involving the nasal mucosa. Patients who have experienced recent nasal surgery or 
trauma should not use a nasal corticosteroid until healing has occurred. PRECAUTIONS AND WARNINGS: Use with caution, if at all, 
in patients with active or quiescent tuberculous infections of the respiratory tract, or in untreated fungal, bacterial, systemic viral 
infections or ocular herpes simplex. There was no evidence of atrophy of the nasal mucosa following 12 months of treatment. Patients 
using Nasonex over several months or longer should be examined periodically for changes in the nasal mucosa. If localised fungal 
infection of the nose or pharynx develops, discontinuance of Nasonex therapy or appropriate treatment may be required. Persistence 
of nasopharyngeal irritation may be an indication for discontinuing Nasonex. The concomitant use of additional therapy may provide 
additional relief particularly of ocular symptoms. There is no evidence of HPA axis suppression following prolonged treatment with 
Nasonex. Patients who are transferred from long-term administration of systemically active corticosteroids to Nasonex require careful 
attention. The safety and efficacy of Nasonex has not been studied for use in the treatment of unilateral polyps, polyps associated 
with cystic fibrosis, or polyps that completely obstruct the nasal cavities. Unilateral polyps that are unusual or irregular in appearance, 
especially if ulcerating or bleeding, should be further evaluated. Patients who are potentially immunosuppressed should be warned of 
the risk of exposure to certain infections. Very rarely, nasal septum perforation or increased intraocular pressure have been reported 
following the use of intranasal corticosteroids. Nasonex should only be used in pregnant women, nursing mothers or women of child-
bearing age if the potential benefit justifies the potential risk to the mother, foetus or infant. Growth retardation has been reported in 
children receiving nasal corticosteroids at licensed doses. It is recommended that the height of children receiving prolonged treatment 
with nasal corticosteroids is regularly monitored. If growth is slowed, therapy should be reviewed with the aim of reducing the dose 
of nasal corticosteroid, if possible, to the lowest dose at which effective control of symptoms is maintained. In addition, consideration 
should be given to referring patient to a paediatric specialist. Safety and efficacy of Nasonex Nasal Spray for the treatment of nasal 
polyposis in children and adolescents under 18 years of age have not been studied. Treatment with higher than recommended doses 
may result in clinically significant adrenal suppression. If there is evidence for higher than recommended doses being used, then 
additional systemic corticosteroid cover should be considered during periods of stress or elective surgery. In a placebo-controlled 
clinical trial in which paediatric patients (n=49/group) were administered Nasonex 100 micrograms daily for one year, no reduction 
in growth velocity was observed. INTERACTIONS: A clinical interaction study was conducted with loratadine. No interactions were 
observed. SIDE EFFECTS: Adverse effects commonly reported in clinical trials in adult and adolescent patients include headache, 
epistaxis, pharyngitis, nasal burning, nasal irritation and nasal ulceration. Other less common and rarely reported side effects are 
listed in the SPC. PACKAGE QUANTITIES: 18g per bottle, supplied with a metered-dose manual spray pump actuator which delivers 50 
micrograms per actuation. Legal Category: Prescription Only Medicine. Marketing Authorisation Numbers: 0201/0216 (UK); 277/77/1 
(Ireland). Marketing Authorisation Holder: Schering-Plough Ltd, Shire Park, Welwyn Garden City, Herts., AL7 1TW, UK. Please refer 
to the full SPC text before prescribing this product. Further information is available on request. Adverse events should be reported. 
Reporting forms and information can be found at www.yellowcard.gov.uk (UK) and www.imb.ie (Ireland). Adverse events with this 
product should also be reported to Schering-Plough Drug Safety Department on +44 (0)1707 363773. Date of Revision of Text: August 
2010. Date of Preparation: August 2010 Nasonex/API/08-10/7
Reference: 1. Canonica GW, Bousquet J, Mullol J, Scadding GK, Virchow JC. A survey of the burden of allergic rhinitis in Europe. 
Allergy. 2007;62(Suppl 85):17-25.
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CliniCal Review
Case rePorT 
over the last year, a 23-year-old female with a 
lifelong history of snuffly, runny nose has begun to 
cough and wheeze, especially with exercise. She 
tires easily and falls asleep during the day. on direct 
questioning, she says she snores heavily and wakes 
each morning with dry mouth, has frequent night 
arousals (she wakes often, especially with nightmares 
and jittery limb movements). She also complains of 
anosmia and poor taste and likes a lot of spicy food, 
this becoming more noticeable in past year.
Image shows 
severe nasal mucosal 
swelling with 
oedematous, pre-
polypoid changes. 
Allergy testing 
showed wheal >16 
mms to dust mites, 
grass pollens and cat 
hair.
Conclusion: Severe allergic rhinitis, with sleep 
apnoea and lower airways irritation from untreated 
rhino-sinusitis.
DisCussion
Allergic rhinitis (AR) is more than a trivial irritation 
of the nose. It is often under-diagnosed and poorly 
treated, especially in children, leading to impaired 
quality of life. There are important links between 
untreated nose and sinus allergy and asthma.
The nasal cavity connects directly with the sinuses, 
so inflammation within the nose usually extends fur-
ther and for this reason rhinitis (of whatever origin) is 
more accurately called rhino-sinusitis. Since the nose 
and sinuses link directly with the lungs via a number 
of pathways, it might be wiser to consider the upper 
and lower respiratory tracts as one functioning unit. 
Allergic childhood asthma begins as rhinitis. Early 
and correct intervention can prevent the evolution of 
inflammatory changes within the upper respiratory 
tract spreading to the lungs.
Concomitant AR in asthmatic children is associ-
ated with an increased likelihood of asthma-related 
hospital re-admissions and greater total days spent 
in hospital.
AR is caused by inhaled airborne allergens such as 
dust mites, grass pollens or animal danders. When 
the sufferer is troubled by one allergen only, he/
she has a better chance of control on an SoS basis. 
For example, with a pollen allergy, therapy can be 
focused within a reasonably short time frame. 
Animal allergy can be cured (not a concept used 
often in medicine) by precise identification and 
removal of the animal, combined with an aggressive 
anti-dander cleaning regimen. However dust mite or 
dust mite plus grass pollen sensitivity usually produc-
es a perennial rhinitis and continuous medication. 
This is not easy for parents to accept when the 
patient is a young child facing into a drug regimen 
likely to run for many years. Honesty about this at the 
beginning may help with non-compliance issues. 
House dust mite allergy and other inhalant allergic 
disorders are strongly associated with co-morbid 
asthma and AR.
FeaTures
In the early stages the nasal cavity is irritated by con-
tinuous or intermittent allergen challenge. This leads 
to symptoms of sneezing, rhinorrhoea, blockage and 
the use of lots of tissues. 
The most common indicator is a ‘nasal salute’ 
where the sufferer repeatedly rubs at the nose to 
relieve the itch and discomfort. 
However, with advanced rhinitis the irritative 
features may abate to a ‘silent but blocked’ stage. 
Here there is chronic upper airways obstruction with 
mouth breathing, dropped chin, throat clearing from 
a persisting post-nasal drip and even sleep apnoea.
Close questioning may reveal early symptoms of 
lower airways irritation such as cough (especially at 
night), occasional wheeze or exercise-induced cough 
with wheeze. The patient may complain of undue 
tiredness and a poor sleep pattern.
Inspection of the nasal cavity is a simple proce-
dure and takes less than a minute.  I use an otoscope 
with the widest fitting and sweep the light source 
from the immediate nasal opening to the upper 
recesses. In severe rhinitis, the obstruction may be so 
established that it is impossible to see anything but 
engorged mucosa. 
When not so totally blocked, check for pallor of the 
mucosa; sometimes it can even look pale blue. Ask 
yourself, does the lining look smooth and shiny (and 
thus normal) or is it ‘bubbly’ and pitted and ridged 
from allergen challenge? 
It is not uncommon to see pre-polypoid changes 
or at least oedematous tissue. Ask about loss of taste 
or smell. In chronic rhinitis there can be impairment 
of these senses, smell going first. If either or both is 
diminished then the condition is long standing and 
problematic. 
TreaTMenT
Before initiating any treatment, ideally identify the 
causative allergen. This helps both you and your 
patient’s understanding of the condition, and should 
allow for better co-operation. It is very frustrating for 
patients to hear ‘it could be anything’ or ‘you’ll just 
have to find out yourself’, two of the usual comments 
offered. Allergy investigation involves skin prick test-
ing with results within 10 minutes or a RAST blood 
test (more expensive, results take longer and the 
range of allergens may be limited). 
Whatever you choose, you can then advise 
your patient on anti-allergen avoidance measures. 
Therapeutic intervention involves first unblocking 
the nasal cavity using betamethasone drops taken in 
the head inverted position. How long the drops need 
to be used depends on the degree of obstruction 
but it is imperative your patient continues until the 
blockage regresses sufficiently to allow a follow-up 
nasal spray. 
The only sprays that work and maintain improve-
ment are topical steroids. Dosage, again, depends on 
the severity of the condition and length of symptoms. 
Maintenance topical steroid sprays are no more 
likely to harm the nasal mucosa than inhaled steroids 
damage the bronchial mucosa in asthma. 
Do not treat any degree of allergic rhinitis without 
first unblocking the nose.
Whether treating allergic rhinitis solely or as part 
of your therapeutic intervention for both upper and 
lower airway symptoms, there is concern about the 
total steroid load. If, say, one puff twice daily of your 
chosen nasal spray does not give adequate control, 
then it is tempting to double the dose. 
Equally, correct management of upper airway 
pathology in combined rhinitis and asthma does 
allow for less medication directed towards the lungs. 
Adding in an anti-leukotriene agent offers extra pro-
tection. This combined therapy keeps total steroid 
load to a minimum. 
A combination of both nasal steroid spray and 
oral antihistamine medication have even better out-
comes in rhinitis and consequent asthma control.
In allergic rhinitis, the step-by-step approach 
might be as follows:
• Unblock nasal cavity using betamethasone drops.
• Stabilise nasal mucosa with your preferred topical 
steroid.
• If there is not total control, or repeated break-
through symptoms occur, consider using Singulair 
or Accolate. 
now you have a much better chance of achieving 
symptom control without increased steroid dosage.
This approach is just as effective in asthma as 
rhinitis.
Dusting off your allergy skills
Table 1:
• nasal allergy features can include:
• Snoring.
• Mouth-breathing.
• Impaired sense of smell (and taste in 
chronic, severe cases).
• Sleep apnoea.
Dr Paul Carson considers the treatment options in a case of allergic rhinitis.
Dr Paul Carson is a member of the British 
Society for Allergy & Clinical Immunology 
and the European Academy of Allergy and 
Clinical Immunology.  He is on the board of 
the Irish Lung Foundation.
Dr Paul Carson, Slievemore Clinic, 
Stillorgan,  Co Dublin
 
Table 2:
When managing rhinitis, consider the 
following: 
• Allergic rhinitis may extend into the sinuses 
(rhino-sinusitis).
• Allergic rhinitis may cause upper airway 
symptoms only.
• Allergic rhinitis may provoke lower airway 
symptoms.
• Allergic rhinitis may co-exist with asthma.
• Always look for upper airway pathology 
when treating lower airways symptoms, as 
intervention in the nasal cavity may allow 
for a reduction in anti-asthma drugs.
• Consider anti-leukotriene and anti-
inflammatory anti-histamine compounds as 
steroid-sparing agents.
(A more detailed explanation of the link 
between upper airways pathology and lower 
airway symptoms can be found in: Riccio et al. 
Cytokine pattern in allergic and non-allergic 
chronic rhino-sinusitis in asthmatic children. 
Clin Exp All 2002; 32: 422-6.)
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online migraine/
headache forum for health 
professionals
The Migraine Association of Ireland 
(MAI) has launched a new online 
migraine/headache forum for all 
healthcare professionals.
Available at www.migraine.ie 
under ‘Health Professionals’ the 
online forum contains the very latest 
in news, events and research on 
migraine/headache from around the 
world. It is also a valuable source of 
information on the diagnosis and 
treatment the condition.
Commenting on the launch, the 
CEo of MAI Mr Patrick Little, said 
that the Migraine Association has 
always been a reputable source of 
information for health professionals 
nationwide.
“However, the new forum is 
more than just information – it is an 
interactive, frequently updated space 
that we hope to expand to include 
online training and telemedicine.”
Podcasts and videos will be added 
to the site over the coming weeks, 
as well as powerpoint presentations 
from training seminars, all of which 
will be available to download.
The forum will be overseen by 
a Medical Editorial Board, which 
includes: Dr Eddie o’Sullivan, Director 
of the Cork Headache/Migraine Clinic 
and Ms Esther Tomkins, Specialist 
nurse at the Beaumont Headache/
Migraine Clinic.
The Board will also take questions 
for those who have a query on any 
aspect of migraine/headache – from 
diagnosis to medication to referral 
pathways.
“We encourage all health 
professionals to log on and have a 
look,” said Mr Little, “If they think 
something is missing or would like to 
see some extra features, we welcome 
any suggestions and feedback.”
It is estimated that between 12 
and 15 per cent of Irish people 
suffer from migraine and the 
MAI is a registered charity, which 
provides information, support and 
reassurance to migraine sufferers 
and those with other headache 
disorders. Information is also on 
offer to the families and friends 
of migraineurs and to medical 
professionals.
The MAI also raises awareness of 
migraine throughout Irish society 
in general, as well as in the health 
professional sector. The Association 
supports research into the condition 
and aims to seek out improved 
treatments for people with migraine.
The new online forum is developed 
and updated by the MAI for Health 
Professionals throughout Ireland.
The association encourages health 
professionals with an interest in 
migraine and other headache to 
contribute to the forum. To do so, 
please email: donnawalsh@migraine.ie
new iPhone app for hay 
fever
Sanofi aventis together with the 
Asthma Society of Ireland have come 
together to announce the availability 
of a new, free iPhone application 
called Pollen Alert, which provides 
a daily, provincial assessment of 
pollen levels in Ireland. Hay fever 
is estimated to affect more than 
420,000 Irish people, and 60-80 per 
cent of people with asthma also 
suffer from hay fever.
The new iPhone app Pollen 
Alert grades pollen levels as low, 
moderate, high, or very high and its 
information is based on the work of 
the University of Worcester in the 
UK, which also monitors pollen in 
Ireland. The HSE will use the same 
data for a daily pollen update on 
the HSE website. Pollen Alert can 
be downloaded for free from the 
App Store, or by visiting www.
asthmasociety.ie
The 2010 summer was particularly 
bad for pollen in Ireland, Dr Jean 
Holohan, CEo of the Asthma Society 
of Ireland, explained.
“The cold snap in January delayed 
the spring bloom. Subsequent rain…
created the ‘perfect storm’ in terms 
of pollen and hay fever – these 
are boom conditions for pollen 
production. Uncontrolled hay fever 
or allergic rhinitis is a common 
asthma trigger.”
In Ireland, the biggest cause of 
hay fever is an allergy to the pollen 
created by grass and up to 90 per 
cent of Irish people with hay fever 
are allergic to this type of pollen.
“The highest levels of pollen are 
in rural areas,” said Dr Holohan, “but 
grass pollen still makes its way into 
towns and cities every day. Most 
pollen is released in the morning and 
rises skywards with the heat of the 
day. It then gets swept overland by 
winds and breezes and then it sinks 
back to earth late afternoon or early 
evening as the temperature starts to 
drop. That is why the peak time for 
pollen is mid-morning and between 
4pm and 7pm and this is when 
people are hardest hit.”
Hey fever, which has no cure but 
can be effectively managed, is a 
relatively recent condition that was 
unknown before 1800. The first 
medically described case was in 
1819, but it was not until 1873 that 
the allergic cause of the illness was 
identified.Hay fever rose steadily 
through the 19th century.
iPHa launches the 2010/2011 
edition of medicines.ie on 
Cd-RoM 
The Irish Pharmaceutical Healthcare 
Association (IPHA) has recently 
announced the release of the 
medicines.ie CD-RoM Version 
2010/2011.
The CD-RoM, which is a copy 
of medicines.ie, is sent annually, 
free of charge, to over 7,000 GPs, 
consultants, nurse prescribers, 
nursing homes, community and 
hospital pharmacists in Ireland. It is 
primarily designed for those who 
do not have ready internet access in 
their place of work. Like medicines.
ie the CD-RoM provides Irish-specific 
and reliable, IMB/EMA approved 
information on over 2,000 medicines 
currently available in Ireland.
In 2010 medicines.ie was certified 
with the “Health on the net” (Hon) 
Code Standard for Trustworthy 
Health Information.
The Hon code is the most widely 
accepted reference for online health 
and medical publishers. other recent 
developments on medicines.ie 
include the provision of information 
to help people know more about 
medicines and how to manage 
minor ailments. There is also a 
link to a comprehensive database 
listing details of both ongoing and 
completed clinical trials, globally.
For your free copy of the CD-
RoMplease email: communications@
ipha.ie or call Tel: (01) 660 33 50 .
Planet of the apps
From a new comprehensive online forum on migraine for health professionals 
to a new iPhone App for hay fever, June Shannon reports on a number of new 
developments for the technophiles among you.
www.yourmedicines.ie
New site lists all leading Irish non-prescription medicines
First Irish online reference site devoted to promoting self care
Site also contains information about illnesses and the proper use of OTC 
medicines available for their treatment.
Edited by Dr Martin Henman, the new site not only acts as a reference guide for 
pharmacists and other healthcare professionals, it also aims to encourage the 
public in the correct approach to self-medication.
www.yourmedicines.ie will be supported by an online advertising campaign 
along with promotion in mainstream media.
YourMedicinesIPadNEW.indd   2 13/03/2009   18:30
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Actavis launches Ibuprofen oTC 
Actavis Ireland has launched Buplex on the Irish Market. Buplex is an 
Ibuprofen oTC treatment which will offer consumers up to a 20% saving and 
is available in pharmacies around the country as from 1st october. Actavis 
will support the launch of Buplex with significant investment in in-store 
support material as well as a targeted consumer advertising campaign 
beginning in early 2011.
Buplex provides effective pain relief for mild to moderate pain such as 
headache, migraine headache, dental pain, period pain and fever. Buplex 
is available in striking and compact packs of 200mg tablets x 12 (€1.70), 24 
(€2.82) and 50 (€4.88) Film-coated Tablets.
Tony Hynds, MD of Actavis Ireland said, “Actavis is delighted to introduce 
Buplex to the Irish market and its launch is an important addition to our 
growing oTC range. We believe Buplex will provide more choice and value 
for Irish consumers.”
Actavis introduces new packaging for 
Floxapen Syrup 125mg/5ml & 250mg/ 
5ml powder for oral suspension
Actavis Ireland has announced the introduction of the newly packaged 
Floxapen Syrup range which is now packaged in cartons. The new look 
packaging, which was acquired by Actavis from GSK in 2007, isavailable as 
from mid September. The introduction of the newly packaged Floxapen 
range is the latest addition 
to Actavis’ growing 
portfolio of products 
introduced to the 
Irish market this year.
Floxapen Syrup 
is indicated for 
the treatment of 
infections due 
to penicillinase 
producing 
straphylococci and 
other gram positive 
organisms susceptible 
to this anti-infective.
Floxapen Syrup 125 mg/5 
ml & 250 mg/5 ml Powder for 
oral Suspension is distributed 
on behalf of Actavis Ireland by 
Allphar.
www.medicalindependent.ie
Actavis adds Piperacillin/Tazobactam 
and Gemcitabine 2g to its hospital 
portfolio 
Actavis Ireland recently 
announced the launch of 
Piperacillin/Tazobactam 
and Gemcitabine 2g to 
its growing portfolio of 
hospital products.
Antibiotic Piperacillin/
Tazobactam 2g/0.25g 
and 4g/0.5g powder for 
solution for injection or 
infusionis an important 
addition to Actavis’ portfolio 
and demonstrates the 
company’s commitment to 
providing an even broader 
selection of products. The packaging is designed with safety in mind, 
including colour differentiated flip-off tops on the vial, total strength shown 
on the carton, and a warning bar that it contains penicillin on the external 
packaging.
Gemcitabine 2g is an important addition to the existing Actavis 
Gemcitabine range. Available with Vialshield, this provides protection for 
healthcare professionals working with cytotoxics by reducing the chance 
of breakage and spillage, thereby minimising 
occupational exposure to cytotoxics.
Tony Hynds, Managing Director at Actavis, 
said: "The addition of these two hospital 
products, is a further extension to our 
growing portfolio and builds on the strong 
recent launches of other hospital products 
including the existing Gemcitabine range and 
Irinotecan."
Actavis has one of the strongest 
development pipelines and robust supply 
chains in the industry. Additional product 
launches are expected over the coming 
months, strengthening Actavis’ expanding 
position in Ireland.
new ESC/EACTS guidelines recommend 
Efient as first-line antiplatelet therapy 
for patients with severe heart attacks 
managed with percutaneous coronary 
intervention 
The Guidelines on Myocardial 
Revascularization were 
presented at the European 
Society for Cardiology 
Congress in Stockholm in 
August and published in 
the European Heart Journal.
The guidelines, from 
the Clinical Guidelines 
Committee of the European 
Society for Cardiology (ESC) and 
the European Association for Cardio-Thoracic Surgery 
(EACTS), also recommend prasugrel for use in patients with less severe heart 
attacks.
Prasugrel received the highest level recommendation (Class I) for use in 
patients with STEMI (ST-elevated myocardial infarction) undergoing PCI, 
irrespective of the patient’s genetic status as the presence of the CyP2C19 allele 
did not influence the action of prasugrel on platelet function, and regardless of 
concomitant proton pump inhibitor (PPI) use.
The Guidelines Committee also recommend prasugrel, for its “usefulness and 
efficacy” in patients with non-ST elevated myocardial infarction (nSTEMI) (Class 
II recommendation). In diabetic patients presenting with ACS, the guidelines 
state prasugrel offers “a significant advantage over clopidogrel without 
increased bleeding”. The guidelines also state that “prasugrel should be used in 
patients who present with stent thrombosis whilst taking clopidogrel”.
“These guidelines provide clear recommendations for how prasugrel should 
be incorporated into medical practice to help reduce the risk of cardiovascular 
events such as heart attacks and blood clots forming around stents,” said Dr 
Joerg Rustige, Leader Cardiovascular Medical ACE, Eli Lilly and Company.
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novartis gains FDA approval for 
Gilenya, an oral first-line MS treatment 
The FDA has approved the oral multiple sclerosis (MS) treatment Gilenya 
(fingolimod) 0.5 mg daily, novartis has announced. A first-line treatment 
for relapsing forms of multiple sclerosis – the most common forms of 
the disease – Gilenya the first FDA approved oral treatment indicated for 
relapsing forms of MS available in the US.
Gilenya reduces the frequency of MS relapses (flare-ups) and helps slow 
the build-up of some of the physical problems caused by MS. Gilenya 0.5 mg 
reduced relapses by 52% (P<0.001) at one year compared with interferon 
beta-1a IM (Avonex®), one of the most commonly prescribed treatments for 
MS. In clinical trials, Gilenya had a well-studied safety and tolerability profile, 
which has been characterized in over 2,600 clinical trial patients, some of 
whom are in their seventh year of treatment, with more than 4,500 patient 
years of experience.
The Gilenya approval was based on the largest clinical trial program 
ever submitted to date to the FDA for a new MS drug. It combined data 
from clinical studies showing significant efficacy in reducing relapses, the 
risk of disability progression, and the number of brain lesions detected by 
magnetic resonance imaging (MRI), a measure of disease activity, in people 
with relapsing forms of MS.
Commenting on the FDA approval, Professor Michael Hutchinson, 
Principal Investigator of the Freedoms Trail at St Vincent’s Hospital, added: 
“The future for treatment of multiple sclerosis with this new powerful oral 
therapy looks good’.
Gilenya was submitted to the European Medicines Agency (EMA) and to 
the US Food and Drug Administration for review in December 2009. The 
EMA regulatory review and other filings worldwide are ongoing.
Effaclar Pharmacy Promotion for oily to 
acne prone skin
La roche-Posay is offering 
complimentary travel size effaclar 
Purifying Foaming gel (worth €3.38) 
within the effaclar Moisturiser value 
sets. Choose the Effaclar Moisturiser 
Value Set suitable to your type of oily 
sensitive skin, which costs the same price 
as your regular full size Effaclar moisturiser, 
and receive a complimentary travel size 
cleansing Gel (while stocks last).
effaclar Moisturiser value sets:
• Effaclar K 30ml Transform the skin’s 
texture with this daily renewal fluid. 
• Effaclar M 40ml oil-free emulsion 
neutralises shine at source for a 
lastingly matte, clear and balanced skin.
• Effaclar Duo 30ml Corrective and 
unblocking anti-imperfection moisturizer for mixed acne.
Cleanse and purify: 
Effaclar Purifying Foaming Gel (200ml RRP€13.50) is a daily purifying 
foaming gel for the face & body. The formula, which contains optimised 
concentration of cleansing agents, is soap-free, colorant-free, alcohol-free 
and paraben-free. It gently cleanses the skin thanks to its high-tolerance 
washing base while purifying the epidermis & eliminating excess sebum.
Erectile dysfunction website – Man 
Matters – relaunched
Eli Lilly has relaunched its 
popular www.manmatters.ie 
website. The new look website 
offers information on erectile 
dysfunction (ED) including 
common symptoms of the 
condition and the treatment 
options available. The website 
is a core component of a 
nationwide health education 
initiative to highlight the 
condition amongst men and 
their partners.
The easy-to-navigate website 
provides clear and concise 
information on ED and aims to 
assist men in discussing the condition with their healthcare professional.
Mary o’Conor, Psychosexual Therapist, advises men to seek professional 
help early: “There may be an embarrassment associated with ED, but don’t 
let that get in your way. Many Irish men don’t realise just how common the 
condition is and that most cases are treatable. Manmatters.ie will help Irish 
men to take the first step in tackling the condition with their healthcare 
professional.”
The website also contains an online self-test questionnaire to help 
men identify the presence of erection problems and encourage them to 
approach their doctor about it.
Manmatters.ie also provides the details of a number of organisations such 
as Marriage and Relationship Counselling Services (MRCS), the Catholic 
Marriage Counselling Service (ACCoRD) and The Diabetes Federation of 
Ireland, who may be able to provide additional help and advice. It also 
offers PDF versions of all of the Manmatters patient information booklets for 
download.
The website is part of the Man Matters campaign, sponsored by Lilly 
Ireland, which challenges men to Get Informed; Get Checked; Act and see 
their doctor as the first step to getting help for any health concerns.
www.medicalindependent.ie
Atrial fibrillation registry reveals 
poor AF control and high rates of CV 
hospitalisation 
Sanofi-aventis announced recently that results from the RealiseAF (Real-
life global survey evaluating patients with Atrial Fibrillation) registry show 
that control of atrial fibrillation (AF) (defined by the 2006 ACC/AHA/ESC AF 
guidelines as either sinus rhythm or AF with heart rate at rest ≤ 80 bpm)1 
was not achieved in more than 40 percent of the AF patients included in this 
10,000 patient cross-sectional registry, as presented during the European 
Society of Cardiology Congress in Stockholm, Sweden. In addition, the 
registry revealed that a majority of patients complain of symptoms, even 
when AF is controlled 2 (55.7 percent).
Importantly, cardiovascular (CV) events were very frequent in this 
population, with a high rate of concomitant CV risk factors (72.2% of patients 
were hypertensive and 46.3% of patients had dyslipidemia) 28.7 percent 
of AF patients suffered from CV events such as acute coronary syndrome 
(ACS) acute heart failure or stroke, leading to an unplanned hospitalisation 
during the last 12 months and 12.4 percent of patients requiring major CV 
interventions such as percutaneous coronary intervention (PCI), coronary 
artery bypass graft (CABG) or valvular surgery.
Management of AF in a real-life setting shows that today, AF is not treated 
according to the 2006 ACC/AHA/ESC AF guidelines:
20 percent of AF patients with structural heart disease received Class Ic 
AADs, despite its contraindication in this patient population. 49.9 percent of 
evaluated paroxysmal and persistent AF patients without congestive heart 
failure (CHF) or hypertension with significant left ventricular hypertrophy 
received amiodarone as a first-line treatment, despite guidelines 
recommendations that it be used as a second line agent.
In addition, patients with a CHADS2 who should receive anti-coagulants 
agents only received these agents in 52 percent of cases.
The RealiseAF registry has a number of Irish sites. Commenting on the 
results Dr Jim o’neill, Consultant Cardiologist at Connolly and the Mater 
Hospitals who was on the international steering committee for the study, 
stated “There was a strong representation from Irish centres in this study, 
indicating that we can perform meaningful clinical research in this country. 
The data accrued indicate that, on a worldwide basis, our management of 
atrial fibrillation remains sub-optimal and that intensive efforts are required 
to lower the morbidity and mortality which is associated with this commonly 
encountered clinical conundrum.”
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Level of bacteria on lift buttons three 
times higher than on public toilet seat
 
The number of bacteria present on a lift button is more than three times 
higher than on a public toilet seat, according to new findings.
Research carried out in hotels, restaurants, banks, offices and airports, 
showed that the level of bacteria on lift buttons averaged 2,200 colony 
forming units per square centimetre, compared to 8 on the average public 
toilet seat.
Among the common bacteria likely to be found are E-coli, Staph-aureus 
and MRSA.
Dr nicholas Moon Ph.D, Director of Technical and Regulatory Affairs at 
Microban Europe, for which the research was carried out, explained: “In a 
busy building, a lift button can be touched by dozens of different people 
who will have come into contact with all kinds of bacteria every hour. Even if 
the buttons are cleaned regularly, the potential for the build up of bacteria 
is high.
Microban antibacterial protection is designed to be incorporated into 
products such as plastic life buttons at the point of production, providing 
durable antibacterial and antifungal protection that lasts the useful life of 
the product.
The company uses a wide range of technologies to suit each specific 
application but predominantly makes use of third generation silver. on 
untreated products, bacteria can potentially double in number in 20 minutes 
but Microban disrupts their functioning, usually causing them to die within 
24 hours.
A dedicated certification programme ensures that quality testing is 
regularly carried out on all products carrying the Microban branding 
and that antibacterial claims are technically supported. This allows 
manufacturers utilising Microban to use robust claims about their efficacy – 
for example, “preventing 99.9% of bacteria.”
Further information: http://www.cisionwire.com
www.yourmedicines.ie
Eczema awareness
Eczema Awareness Week takes place from 19-25th September aims to raise 
awareness about eczema and its impact on sufferers of the condition. It is 
organized by the Irish Eczema Society and is supported by La Roche-Posay. 
For further information see www.eczemaireland.org or your local pharmacy.
In support of Eczema Awareness Week, La Roche-Posay is running a Dry 
Skin Promotion in pharmacies nationwide this autumn while stocks last. Buy 
a 400ml pump from the Lipikar range and save 33%
RRP with the 33% Saving: 
• Lipikar Balm AP  RRP €12.39 (Saving €6.11) 
• Lipikar Milk  RRP €10.38 (Saving €5.12)
• Lipikar Surgras  RRP €9.04 (Saving €4.46)
• Lipikar Syndet  RRP €9.04 (Saving €4.46)
Each Lipikar Baume AP 400ml will also have a leaflet 
attached, providing tips and information on how to manage 
eczema on a daily basis.
Lipikar baume aP is a lipid replenishing body balm with 
a 24hr anti-scratch efficacy for severely dry to eczema-
prone skin in children and adults. Lipikar baume aP offers 
an anti-scratch efficacy thanks to a high concentration of 
niacinamide 4%. This ingredient inhibits histamine, a 
precursor of inflammation. This allows a break in the “itch-
scratch cycle”, providing an opportunity for the cutaneous 
barrier to be healed thanks to the repairing active 
ingredients within Lipikar Baume AP and the skin’s own 
natural defences. niacinamide is an active ingredient that 
also helps restore the cutaneous barrier by boosting lipid production.
Lipikar Baume AP contains 20% shea butter, a reference dermatological 
active ingredient to restore skin comfort, 10% hydrating glycerin, 5% canola 
oil proven to be naturally resistant to oxidation and 1% soothing glycine. 
Lipikar Baume AP also contains La Roche-Posay Thermal Spring water which 
has been dermatologically proven to be anti-free radical, anti-irritant and 
soothing.
Lipikar baume aP has a unique ultra-penetrating texture, which has been 
designed to be a “quick dress texture” to encourage compliance. It is both 
fragrance-free and paraben-free.
new Carmex Strawberry lipbalm
new Carmex Strawberry combines all of Carmex award winning moisturising 
and protecting ingredients with a subtle hint of strawberry, reminiscent of 
ice cold strawberry milkshakes and gets to work fast, tending to chapped, 
sore and dry lips, leaving them soft and smooth.
Carmex Strawberry also protects lips from UV damage with the added 
benefits of SPF 15. not only is it a great sunscreen, you can wear it long after 
summer as an undercoat to lipstick or on its own to give your lips a natural 
healthy shine. 
A plump and pretty pout makes your entire face look younger and Carmex 
Strawberry lip balm’s combination of rich emollients including menthol, 
camphor and beeswax lock in moisture and banish dryness after only one 
application leaving a gorgeous tingling effect on the lips, encouraging a 
healthy appearance.
Carmex award-winning formula was created in 1937 by Alfred Woelbing, 
whose family still run the business today. Carmex also comes in original and 
Cherry flavour. 
oral single dose drug Rivaroxaban 
successfully meets primary efficacy 
outcome and demonstrates similar 
safety to standard therapy
Results of the Phase III EInSTEIn-DVT clinical trial of the oral anticoagulant 
Rivaroxaban demonstrated non-inferiority compared to the standard of care 
for the prevention of recurrent venous thromboembolism (VTE) in patients 
with acute symptomatic deep vein thrombosis (DVT), with a comparable 
safety profile. The data were presented today during a Hot Line session at 
the European Society of Cardiology (ESC) Congress.
“Results from EInSTEIn-DVT could transform the way physicians treat 
deep vein thrombosis,” said lead investigator Dr Harry R Büller, Academic 
Medical Center in Amsterdam, netherlands, who presented the results. 
"While the current standard of care is effective when well-controlled, it is 
often associated with significant drawbacks for patients and physicians. 
A novel single-drug approach such as oral Rivaroxaban could potentially 
provide an effective and well-tolerated, simple, fixed-dose regimen for the 
treatment of deep vein thrombosis as a replacement for current standard 
therapy.”
In the study, oral rivaroxaban demonstrated non-inferiority for the 
primary efficacy outcome, defined as the cumulative incidence of 
symptomatic recurrent DVT and non-fatal or fatal PE, in patients with acute 
symptomatic DVT. This regime was compared with the current standard of 
care of enoxaparin followed by a vitamin K antagonist (VKA) [2.1% vs. 3.0%, 
respectively (p <0.0001 for non-inferiority)]. Rivaroxaban demonstrated 
similar results compared to the standard of care for the principal safety 
outcome measuring a composite of major and non-major clinically relevant 
bleeding events [8.1% in both treatment groups, (p=0.77)]. Monthly liver 
function tests did not reveal a signal for impaired liver safety.
net clinical benefit, a pre-specified secondary outcome defined as 
the composite of the primary efficacy outcome plus major bleeding, 
demonstrated an improvement for Rivaroxaban compared to standard 
therapy (2.9% vs. 4.2%, respectively; HR of 0.67, CI: 0.47 – 0.95). other 
presented secondary outcomes, including all-cause mortality (2.2% vs. 
2.9%, respectively; HR of 0.67, CI: 0.44 – 1.02) and cardiovascular events 
(0.7% vs. 0.8%, respectively; HR of 0.85, CI: 0.39 – 1.85) were not statistically 
significantly different.
EInSTEIn-DVT is the sixth Phase III trial in the ongoing rivaroxaban 
global development programme that demonstrated either non-inferiority 
(EInSTEIn-DVT) or superiority (RECoRD 1-4 and EInSTEIn-EXTEnSIon) 
compared to current anticoagulant therapies.
Protocol:
42 patients aged 20 to 43 with oily acne-prone skin with at least 5 inflammatory 
lesions and 10 retentional lesions. 4 weeks of use. 1 application per day. Clinical 
score by counting lesions at T0 and T4 weeks by dermatologist.                                                             
LA ROCHE-POSAY. COMMITTED TO DERMATOLOGY.
www.laroche-posay.ie
Clinically proven efficacy
Results after only 1 month,  
1 application per day
-31% reduction of inflammatory acne
-16% reduction of retentional acne 
Major breakthrough tested on acne-prone skin
EFFACLAR DUO
Severe imperfections and  
sebum-blocked pores:  
one care, dual action.
Young skin innovation
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Electro-stimulation from RoC – for the 
first time in a cream! 
Harnessing the power of bioelectricity, Johnson & Johnson introduce the 
next revolution in anti-ageing RoC Sublime Energy with unique, patented 
E-PULSE Skin Electro-Stimulation Technology. Using a unique 2-step process 
designed to mimic the body’s own bioelectricity, the range combines 
energised particles of zinc and copper, which act as ‘miniaturised batteries’ 
that help to jumpstart the skin. When the activating moisturiser is then 
applied to the skin, the product mimics the body’s own bioelectricity to 
accelerate the skin’s repair and rejuvenating process**. This is the first 
technology that delivers biological levels of electric signals similar to the 
skin’s natural bioelectricity in a topical treatment – new RoC® Sublime 
Energy™. It is clinically proven to increase elastin and collagen production 
and clinical tests show visible results in just 3 hours*** – the effect has been 
likened to sending an e-mail to the skin instead of a letter!
E-PULSE Electro Stimulation Technology™ can only be found in new RoC® 
Sublime Energy™. Clinical tests show visible results in just 3 hours***
superior anti-ageing action – appearance of fine lines, dark circles, eye 
folds, under eye bags and upper eyelids puffiness is reduced
immediate results – clinical tests show visible 
results in just 3 hours
Tolerance – Self-assessment of 1,000 
women proved 100% tolerance. Clinical 
tests found it is mild enough for use even 
in the delicate eye area and did not cause 
sensitivity or irritation.
The range
RoC® Sublime Energy Eye 
RoC® Sublime Energy Day SPF 20 
RoC® Sublime Energy night 
Roger & Gallet – the perfect gift for 
Christmas 
roger & gallet creates Huile sublime dry oil within the Bois d’orange 
fragrance offering which also includes soap, body lotion and fragrant water.
roger & gallet, whose perfumes promote well-being through the powers 
of Aromachology, recently launched in pharmacies in Ireland. Concentrated 
in rare natural essences and essential oils, these fragrant ranges offer a 
complete sensory experience: perfumed waters, as well as round and liquid 
soaps, shower gels and body milks to provide a unique moment of pleasure 
every day.
roger & gallet Huile sublime is a perfumed dry oil that can be used on 
the face, body and hair. It delicately envelops the skin in its heavenly scent, 
leaving a sun-kissed satin sheen that is both nourishing and protective.
Huile sublime bois d’orange moisturises and softens skin, helping to 
protect its vigor. This sublime oil is composed of a unique combination of six 
active vegetable oils:
• Argan oil prevents skin from drying out,
• Almond oil softens the skin,
• Camelia oil helps restore suppleness and elasticity,
• Macadamia oil nourishes the epidermis,
• Evening primrose oil helps protect the skin,
• Sesame oil is a emollient.
The formula is also enriched with Vitamin E, recognised for its anti-oxidant 
properties and invigorating orange essential oil.
Tested under dermatological supervision, silicon-free and non-
comedogenic; Bois d’orange dry oil is suitable for dry and sensitive skin.
a sense of well-being
This harmony of wooded and zesty notes is made up of the essential 
oils of Mediterranean citrus fruits (mandarin, orange and bitter orange), 
combined with the fruity sweetness of orange blossom, the feminine scents 
of jasmine and the woodland sensuality of Atlas cedar.
Trust Flexitol Heel Balm
Flexitol Heel Balm is specially formulated for the treatment 
of rough, dry and cracked feet. It's the number 1 foot treat-
ment in Australia and UK and now Irish people can benefit 
from its unique formulation. 
Flexitol Heel Balm contains:
• 25% Urea for removal of dead skin cells
• emollients to penetrate and smooth hard skin
• occlusive properties creating a barrier function
• moisturisers to keep skin supple
 
Apply Flexitol Heel Balm should be applied twice daily, 
morning and night to rough, dry and thickened skin on 
feet. once the skin is restored continued use is advised to 
maintain condition and keep feet in tip-top condition all year long..
www.medicalindependent.ie
Changes to CoZAAR Comp packaging
MSD has announced that they will gradually be introducing new packaging 
across all three presentations of CoZAAR Comp in Ireland. This will affect the 
appearance of the outer cartons, blister foils and patient information leaflets of 
all CoZAAR Comp presentations: CoZAAR Comp 50mg/12.5mg, CoZAAR Comp 
100mg/12.5mg and CoZAAR Comp 100mg/25mg
In summary these changes are as follows:
• Standardisation of the colour schemes of the outer cartons across the 
presentations.
• To distinguish between the ranges, the colour of the product name has been 
adjusted.
• To distinguish between the doses, colour coding across the various 
strengths has been used.
no changes are being made to the appearance of the tablets themselves.
Please note that existing stocks are not being withdrawn and should be 
depleted as normal until replenished with the new packaging from your supplier.
Further information: Margaret Walsh at margaret_walshe@merck.com
Prolia (denosumab): unique new 
treatment for post-menopausal 
osteoporosis 
Amgen Ireland and GlaxoSmithKline (Ireland) Ltd (GSK) recently announced 
that denosumab has become available in Ireland to treat osteoporosis in 
post-menopausal women at increased risk of fracture and will be reimbursed 
under the GMS and DPS as of 1st october. 
With proven efficacy and a six-monthly injection, denosumab offers 
women with osteoporosis a new alternative to current treatments. 
Denosumab works in a different way from other osteoporosis treatments. 
It is the first and only approved therapy that specifically targets RAnK ligand, 
an essential regulator of osteoclasts (the cells that break down bone). 
Denosumab helps stop the process that causes bone loss throughout the 
skeleton, resulting in greater bone density, stronger bones, and reduced risk 
for fractures at the spine, hip and other non-vertebral sites.
The reimbursement for denosumab follows a review of the therapy’s cost-
effectiveness by the (nCPE for the prevention of osteoporotic fractures in 
postmenopausal women.
Dr Gillian Darling, GP Specialist in Women's Health in Leopardstown and 
the Dublin Well Woman Centres commented: As most osteoporosis patients 
are treated in primary care it is an advantage to have a treatment that can be 
administered in the GP surgery as well as the hospital clinic setting. 
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Simponi – first once-monthly 
subcutaneous anti-TnF for RA, PsA and 
AS with novel SmartJect prefilled pen
MSD has announced the launch of SIMPonI (GoLIMUMAB) the first once-
monthly, subcutaneous therapy for the treatment of moderately-to-severely, 
active rheumatoid arthritis (RA) in combination with methotrexate, active and 
progressive psoriatic arthritis (PsA) and severe, active ankylosing spondylitis (AS).
Simponi is approved as a 50mg subcutaneous injection once a month and is 
indicated:
• In combination with methotrexate, for the treatment of moderate-
to-severe, active RA in adult patients when the response to disease-
modifying anti-rheumatic drug (DMARD) therapy, including 
methotrexate, has been inadequate. Simponi has also been shown to 
improve physical function in this patient population.
• Alone or in combination with methotrexate, for the treatment of active 
and progressive PsA in adult patients when the response to previous 
DMARD therapy has been inadequate. Simponi has also been shown to 
improve physical function in this patient population.
• For the treatment of severe, active AS in adult patients who have 
responded inadequately to conventional therapy. 1
Dr Colm Galligan, Medical Director, MSD commented; "Simponi expands upon 
MSD's leading immunology franchise in providing treatment options that meet 
the needs of both the patient and healthcare professional. In SIMPonI we can now 
offer rheumatologists and their patients an effective once-monthly subcutaneous 
dosing option to go towards improving the lives of patients most affected by RA, 
PsA and AS."
The efficacy and safety of SIMPonI has been studied in a comprehensive Phase 
III development programme in over 2300 rheumatology patients living with 
moderately to severely active RA, Active PsA and Active AS. In Phase III rheumatoid 
arthritis trials, Simponi was shown to be effective regardless of prior treatment 
experience, which included patients inadequately responding to methotrexate 
and patients previously treated with anti-TnF agents.
Simponi is available as a state-of-the-art Smartject prefilled pen which has been 
developed with rheumatoid arthritis patients in mind and includes many patient-
focused features. These features include: a large side button, auto-
retract needle for added safety, a 
large observation window so it is 
easy to see when the full dose has 
been administered, a security seal 
for extra protection and an easy-
twist cap.
new formulation of Stelara provides 
greater convenience for patients with 
moderate to severe plaque psoriasis
Janssen-Cilag have announced that a pre-filled syringe formulation of 
Stelara (ustekinumab) is now available in Ireland for the treatment of 
moderate to severe plaque psoriasis following recent approval by the 
European Commission. The pre-filled syringe provides convenience, making 
it easier for patients to self-administer their treatment. It will be available in 
both 45mg and 90 mg doses.
Stelara, a first in class biologic, has demonstrated significant 
improvements in patients’ psoriasis and quality of life in three Phase 
III studies which included a total of more than 2,800 patients. These 
improvements were sustained with as few as four injections a year (every 12 
weeks) following two starter doses at weeks 0 and 4.
"The pre-filled syringe should make the administration of Stelara 
far quicker and easier for patients.” says Dr Brian Kirby, Consultant 
Dermatologist at St Vincent’s, University Hospital. “This new development 
will give patients with moderate to severe psoriasis a greater sense of control 
of their disease. As Stelara is only administered 4 times per year this allows 
patients to live normal lives rather than spend time managing their disease."
In patients weighing more than 100 kg, where a 90 mg dose is 
recommended, patients now have an additional convenience of a single 
injection with the 90 mg prefilled syringe.
Support Breast Cancer Research and 
launch limited edition – neoVadiol Gf 
In support of the Breast Cancer 
Awareness month in october, 
Vichy are launching Limited Edition 
neoVadiol Gf Day & night Sets ffering 
a saving of 33%. Sets are available 
in pharmacies nationwide from 
october while stocks last. For Breast 
Cancer Awareness month, Vichy have 
partnered with national Breast Cancer Research Institute 
(nBCRI) and make a contribution to nBCRI for every value set purchased.
Menopausal Skin Insights: The change in hormonal activity during the 
menopause often affects three key areas of the face: cheekbones lose definition, 
facial contours are less sharp and the neck tends to thicken.
new generation formula to re-inforce the skin’s support tissues: neoVadiol Gf 
Intensive Densifying Care targets the signs of menopausal skin ageing. It contains 
the exclusive combination of Pro-Xylane & Proteic Gf, two ingredients of natural 
origin, to stimulate the production of Growth Factors. Growth Factors are proteins 
naturally present in the skin and play a fundamental role in preserving skin density.
In-vitro tests: For the firsttime, Vichy Laboratoires transfer the techniques of in-
vitro tissue support in a unique skincare, neoVadiol Gf. In-vitro tests demonstrate 
that within 10 days Proteic Gf stimulates the production of Growth Factors and Pro-
Xylane™ restores the extra-cellular matrix, the pool of growth factors. Skin density 
is improved and layers are more structured.
Results: The proven efficacy of neoVadiol Gf was demonstrated in a multi-
centric clinical study carried out on a panel of 220 women in 4 countries. The 
results: cheekbones are re-modeled. The neck is more toned. The jawline is re-
defined.
Ativan (Iorazepam) 4mg/ml Solution 
for Injection (PA 22/1/3) 
Pfizer Healthcare Ireland have made the following announcement regarding 
the current availability of Ativan (Iorazepam) 4mg/ml solution for injection.
A limited amount of stock was received in Ireland recently, and is currently 
available via Cahill May Roberts. Further batches are due to be delivered 
at the beginning of october and in november of this year. It is likely that 
there may be a period during September where Pfizer will be out of stock at 
wholesale level. Pfizer expects that the stock of Ativan 4mg/ml solution for 
injection will be back to normal levels by the end of 2010. This estimate is 
based on current information and may be subject to change. 
PHI regrets any interruption caused by this disruption in supply. 
Please contact the Medical Information department (1800-633363) should 
you require any further information.
Clonmel Healthcare price decreases 
Clonmel Healthcare has significantly reduced the prices of its generic 
prescription branded medicines in line with the HSE Agreement and will 
continue to offer savings to healthcare professionals and patients alike. This 
price reduction is effective as from 1st october 2010
Clonmel would like to highlight that only 30% of their product range is 
affected by this price decrease with the average price drop being approx 
29%. 
If you require any further information, please do not hesitate to contact us 
on 01-620-4000.
www.medicalindependent.ie
issue 9 volume 12 • oCToBeR 2010
46
Classifieds/CRosswoRd
DaTes For your Diary
Diary/CLas
siFieDs serv
iCe 
aT irisH PHa
rMaCisT
Please email 
your ad to 
maura@gree
ncrosspublish
ing.ie
ip Crossword no.179
name:
Address:
E-mail:
Congratulations to the winner of last month’s crossword: 
Mary Evans, Roche's Pharmacy, Main Street, Dunlavin, Co Wicklow.
For a chance to win €70, please send completed entries to: 
the Editor, Irish Pharmacist, GreenCross Publishing, 
7 Adelaide Court, Adelaide Rd, Dublin 2 or 
fax to (01) 478 9779 by 23 october 2010.
Please note the winner's cheque will be issued 45 days after publication.
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across
1 Tim and Ivan produce riboflavin, for instance (7)
4 Spiritual leader found when bunny loses its tail! (5)
7 Extreme politician getting to the root of things, 
perhaps (7)
8 Use a washboard for brushwood! (5)
9 Spinster is game! (3,4)
10 Such car parts may be sparse (6)
12 of the back, in cod or salmon (6)
15 Twist a rope in the great outdoors (4,3)
17 Men do represent the devil! (5)
19 I car-ski erratically and get motion sickness (7)
20 Type of Dane, bear or balls of fire! (5)
21 Hi! Do try unnatural enlargement causing goitre! (7)
Down
1 Bug in a computer programme? (5)
2 Cab found in mare. How gruesome! (7)
3 He used to keep one eye on o’Connell Street. (6)
4 Circular game of golf? (5)
5 Gib’s act tamed lions and tigers (3,4)
6 In Mr. Castro you’ll find an unbeliever! (7)
10 Sound asleep? (7)
11 A solvent for toe acne? (7)
13 A methodical hospital attendant! (7)
14 Turn at twisted absentee (6)
16 Ration that’s a change to all (5)
18 Knead massaged in the nude (5)
oCTober
Wednesday, 20 October
Meningitis Trust’s 
conference, Dublin
The Meningitis Trust is holding 
an all-Ireland 'After-effects' 
conference aimed specifically 
at health professionals at 
Chartered Accountants House 
in Dublin.
The free conference, titled 
‘Aftercare and After-effects’, 
aims to consider the impact 
and the wide range of 
outcomes of the disease and 
highlight the importance of 
specialist support in helping 
those affected to rebuild their 
lives.
Speakers at the conference will 
include Dr Bill Casey, 
Consultant
Anaesthetist from our Lady1s 
Children's Hospital in Crumlin, 
Ms nuala Harmey, 
Bereavement Co-ordinator at 
the Children’s University 
Hospital, Mr Gavin Campbell, 
Prosthetics and orthotics at 
Musgrave Hospital in Belfast, 
and Dr Suzanne Cotter, Public 
Health Specialist, Health 
Protection Surveillance Centre 
in Dublin. 
For information about the 
event and to register, please 
email Ms Moira Shaw at 
moiras@meningitis-trust.ie  
Thursday, 21 October
irish society of Community 
and Public Health Medicine’s 
annual education Day
and AGM, Dublin
The venue for the ISCPHM’s 
annual meeting is the 
Westbury Hotel, Dublin 2,
and registration will take place 
from 9.30am to 10.00am.
Topics discussed on the day 
will include: ‘Motivation and 
Leadership in the Workplace’, 
‘HPV Vaccine’, ‘Emerging 
Infectious Diseases – a Global 
Perspective’ and ‘ 
Epidemiology of Type 1 
Diabetes’. The chairperson for 
the event will be Dr Cathy 
Higgins, President of the 
ISCPHM. 
The cost to attend the 
educational day is €100 for the 
full day (€30 membership 
included in price). Please note 
that CME is available.
For more information, please 
email: info@iscphm.com  
Friday, 29 October
breastfeeding and 
depression conference, 
Dublin
This conference will take place 
at the Alexander Hotel in 
Dublin 2 and is supported by 
the HSE.
The international speaker is Dr 
Kathleen Kendell Tackett.
Room rate of €95 (B&B) for 
conference delegates.
Cost: €40 (to include lunch).
To book, please contact Denise 
via email: denisegarde@gmail.
com or Tel. 086 811 0129
For more information, please 
visit: www.cuidiu-ict.ie
noveMber
Tuesday, 2 November
oLCHC’s Caring for the Child 
with a Life-Limiting 
Condition Programme,
Dublin
The Centre of Children’s nurse 
Education in our Lady’s 
Children’s Hospital, Crumlin 
(oLCHC) is hosting a one-day 
awareness programme at the 
Red Cow Moran Hotel, Dublin, 
on Caring for the Child with a 
Life-Limiting Condition (Level 
A). Funded by the Irish Hospice 
Foundation, this awareness 
programme is for nursing and 
medical personnel, palliative 
care specialists, psychologists, 
social workers and other 
personnel from various 
voluntary and statutory 
organisations who are 
occasionally required to 
provide care for children with 
life-limiting conditions and 
their families. Topics addressed 
include healthcare provision 
for these children, supporting 
social and psychological 
needs, pain and symptom 
assessment and management, 
and ethical perspectives. 
Please note that there is no fee 
for this programme. For 
further details and bookings, 
contact Fiona Woods, 
Programme Co-ordinator on 
Tel. (01) 409 6605 or 087 745 
5952 or email: admin.cllc@
olchc.ie  
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Produced to the highest 
standard, the fl ip-over wire 
bound calendar will make 
an ideal gift for you to give 
to loyal customers while also 
supporting a good cause.
Later this yea
r, 
Irish Pharmac
ist will 
produce a 20
11 calendar 
celebrating t
he history 
of Irish pharm
acy, 
which will be
nefi t the 
Benevolent F
und. 
The calendars will be sold 
in batches of 10.
10 Calendars — €40
20 Calendars — €75
40 Calendars — €120
 
For every calenda
r bought 
by you to distribu
te to your 
customers Irish P
harmacist 
will donate 1 euro
 to the 
Benevolent Fund
.
Contact Louis or graham on: 01 4189799
or by email: calendar@greencrosspublishing.ie
Reward your Customers 
Benevolent Fund
and
Christmasthis
Support
your
To order your copies just send a cheque or money order to:
GreenCross Publishing, 7 Adelaide Court, Adelaide Court, Dublin 2 or phone01 4053590.
last chance to get your calendarsclosing date 15 october
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The law of uninTended consequences
deter anyone from taking what they do need. When 
the tax is set higher, then it is no longer symbolic, 
and can be expected to create problems which could 
negate the income collected by the HSE.
Countries which have had a prescription tax have 
found that there is a sub-section of patients who will stop 
taking medication when it is not free, especially drugs 
that prevent problems getting worse, such as drugs for 
high cholesterol, asthma and blood pressure. The result 
is that some of these people deteriorate to the point that 
they need highly expensive hospital treatment, wiping 
out the financial saving the state made from the unused 
medication. Less dramatic costs will probably also occur 
as people try to ‘get their money’s worth’. For example, 
if a GP has written a pain-killer to be taken ‘as required’ 
without stating a specific quantity, then why would a 
patient just take enough for a few days when a month’s 
supply costs him the same? As GPs get their arms twisted 
by patients we can expect to see two Ventolins, etc. 
instead of one on a lot of GMS prescriptions. Time will tell.
codeine wiThdrawal headache
The new guidelines on the sale of codeine-containing 
products have not yet been in place for long enough 
to assess them. The unfortunate people who are 
already addicted to codeine now have to work much 
harder to get their fix. Hopefully, the wasted time 
and effort involved will encourage some of them to 
face up to the facts of their situation and seek help. 
others will probably get more resourceful and buy 
CCPs online or take daytrips to northern Ireland. This 
was to be expected, and nothing can be done to stop 
it. The real measure of success for the guidelines will 
be whether or not they reduce the number of future 
codeine addicts, although quantifying this reduction 
may be impossible.
Any such reduction will have come at a cost. 
These guidelines have increased the workload for 
pharmacists considerably as they attempt to cope 
with both their dispensary and expanded oTC 
responsibilities. It is inevitable that there will be 
less time spent in the preparation and dispensing 
of prescriptions as pharmacists spend time at 
the counter selling (or refusing to sell) CCPs. It is 
impossible for a pharmacy to always have enough 
pharmacists and support staff on duty for every 
busy spell because it is impossible to predict every 
busy spell – patients do not make appointments to 
bring in prescriptions, or to buy CCPs. Typically in any 
workplace more pressure leads to more errors – let’s 
hope not any serious ones.
The other casualty of these guidelines is the 
relationship between us and the public. Painkillers 
containing codeine are popular because they are 
effective, and if people need them they don’t 
appreciate getting a lecture instead. For example, a 
family friend of mine who is a decent, upstanding, 
articulate, intelligent lady in her thirties was recently 
in considerable pain from her wisdom teeth. She 
went to a local pharmacy to buy nurofen Plus, and 
the pharmacist refused to sell her any. She left the 
pharmacy annoyed and in her words ‘feeling like a 
criminal’. She will never set foot in that pharmacy 
again. This kind of story has happened all over the 
country and considerable damage is being done to 
our reputation as healthcare professionals who are 
approachable and helpful. This reputation has always 
served us well, and in turn enabled us to serve the 
public well. As we stand at the counter trying to sort 
the sheep from the goats, let’s remember that.
CONTACT US NOW  1850 313131
or sales@cruinn.ie 
FAST
Two minutes for a full Lipid Profile.
40 seconds for a Glucose Test.
SAMPLE SIZE
Finger prick sample, 15 – 40 µL.
EASY
Minimal training required for Pharmacists,
Technicians and OTC staff which is supported 
by our medical and scientific staff.
QUALITY CONTROL
Internal and external quality control support
programmes ensures confidence in results
TEMPERATURE
No refrigeration required for strips or controls.
PORTABLE
Hand held and battery operated.
CONNECTIVITY
Printer and computer connectivity option
available.
CE-MARKED
FDA-CLEARED 
CRMLN-CERTIFIED
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t is a fact of life that well-intentioned actions 
can often have results that create 
new problems, or even be counter-
productive in terms of how they 
affect the original problem. For 
instance the introduction of bin 
charges in Dublin led to a trebling 
of the number of admissions to St James’s 
Hospital for burns victims injured while 
burning household rubbish in their back 
gardens. The positive intended effect of 
the bin charges was that people were 
incentivised to recycle to save money, yet 
the benefits to the environment of this 
increased recycling are undermined by 
illegal dumping, and by DIy incineration 
leading to air pollution.
It will be interesting to see what the consequences 
will be of the 50 cent prescription tax on medical 
card prescriptions. I have in the past written that 
I thought a tax of this sort would be a good 
thing; I may be the only pharmacist in the 
country to hold this opinion. However, I had 
always envisaged a token payment of maybe 
10 cent an item, just to let patients realise 
that medication has a cost, and should be 
respected, not taken for granted. It is clear, 
despite what they have said publicly, that 
the HSE bean-counters have gone for 50 
cent an item in order to raise revenue. 
Maybe I’m splitting hairs, but in my 
humble opinion a 10 cent charge should 
be enough to make someone think twice 
before wasting medication, but should not 
